$trup 2024 Q1 10-K

Concept	2024 Q1	2023 Q4	2023
Revenue	$306.1M	$295.9M	$1.109B
YoY Change	19.43%	20.26%	22.47%
Cost Of Revenue	$269.9M	$255.8M	$977.6M
YoY Change	17.35%	20.45%	24.85%
Gross Profit	$36.23M	$40.06M	$131.0M
YoY Change	37.5%	19.06%	7.23%
Gross Profit Margin	11.83%	13.54%	11.82%
Selling, General & Admin	$31.52M	$30.58M	$137.6M
YoY Change	-26.12%	-7.42%	6.75%
% of Gross Profit	87.0%	76.33%	105.01%
Research & Development	$6.960M	$5.969M	$21.40M
YoY Change	42.04%	-14.18%	-14.84%
% of Gross Profit	19.21%	14.9%	16.34%
Depreciation & Amortization	$3.785M	$3.024M	$12.47M
YoY Change	18.21%	4.38%	14.22%
% of Gross Profit	10.45%	7.55%	9.52%
Operating Expenses	$42.26M	$39.58M	$171.5M
YoY Change	-16.75%	-7.71%	3.95%
Operating Profit	-$6.137M	$487.0K	-$40.66M
YoY Change	-74.94%	-105.28%	-5.45%
Interest Expense	$3.596M	-$3.776M	$12.08M
YoY Change	50.65%	125.84%	183.03%
% of Operating Profit		-775.36%
Other Income/Expense, Net	$2.843M	$1.256M	$7.701M
YoY Change	49.47%	-16.49%	148.42%
Pretax Income	-$6.890M	-$2.033M	-$45.04M
YoY Change	-72.41%	-78.14%	1.9%
Income Tax	-$38.00K	$130.0K	-$342.0K
% Of Pretax Income
Net Earnings	-$6.852M	-$2.163M	-$44.69M
YoY Change	-72.35%	-76.7%	0.05%
Net Earnings / Revenue	-2.24%	-0.73%	-4.03%
Basic Earnings Per Share	-$0.16		-$1.08
Diluted Earnings Per Share	-$0.16	-$0.05	-$1.08
COMMON SHARES
Basic Shares Outstanding	41.81M shares	41.55M shares	41.44M shares
Diluted Shares Outstanding	41.92M shares		41.44M shares

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$275.2M	$277.2M	$277.2M
YoY Change	12.49%	24.62%	24.62%
Cash & Equivalents	$146.5M	$147.5M	$147.5M
Short-Term Investments	$128.7M	$129.7M	$129.7M
Other Short-Term Assets	$17.08M	$17.02M	$17.02M
YoY Change	-2.33%	19.47%	19.47%
Inventory
Prepaid Expenses
Receivables	$278.5M	$267.9M	$267.9M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$570.8M	$562.1M	$562.1M
YoY Change	11.84%	19.82%	19.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$104.4M	$103.7M	$103.7M
YoY Change	10.47%	14.28%	14.28%
Goodwill	$42.98M	$43.71M
YoY Change	-0.11%	4.12%
Intangibles	$17.22M	$18.75M
YoY Change	-25.2%	-22.0%
Long-Term Investments	$13.01M	$300.0K	$12.87M
YoY Change	54.11%	0.0%	45.53%
Other Assets	$18.01M	$18.92M	$41.89M
YoY Change	-7.83%	-0.11%	13.28%
Total Long-Term Assets	$218.7M	$220.9M	$220.9M
YoY Change	5.37%	9.05%	9.05%
TOTAL ASSETS
Total Short-Term Assets	$570.8M	$562.1M	$562.1M
Total Long-Term Assets	$218.7M	$220.9M	$220.9M
Total Assets	$789.5M	$782.9M	$782.9M
YoY Change	9.97%	16.57%	16.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.348M	$10.51M	$10.51M
YoY Change	13.06%	10.92%	10.92%
Accrued Expenses	$30.47M	$34.05M	$34.05M
YoY Change	3.09%	4.4%	4.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.350M	$1.350M	$1.350M
YoY Change	6.89%	22.39%	22.39%
Total Short-Term Liabilities	$351.6M	$344.5M	$344.5M
YoY Change	12.68%	18.94%	18.94%
LONG-TERM LIABILITIES
Long-Term Debt	$127.5M	$127.6M	$127.6M
YoY Change	23.85%	86.65%	86.65%
Other Long-Term Liabilities	$4.627M	$4.487M	$4.487M
YoY Change	-7.9%	-9.68%	-9.68%
Total Long-Term Liabilities	$132.1M	$4.487M	$132.1M
YoY Change	22.37%	-9.68%	80.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$351.6M	$344.5M	$344.5M
Total Long-Term Liabilities	$132.1M	$4.487M	$132.1M
Total Liabilities	$486.1M	$479.2M	$479.2M
YoY Change	14.89%	30.82%	30.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$223.1M	-$216.3M
YoY Change	13.63%	26.05%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$16.53M	$16.53M
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$303.4M	$303.7M	$303.7M
YoY Change
Total Liabilities & Shareholders Equity	$789.5M	$782.9M	$782.9M
YoY Change	9.97%	16.57%	16.57%

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.852M	-$2.163M	-$44.69M
YoY Change	-72.35%	-76.7%	0.05%
Depreciation, Depletion And Amortization	$3.785M	$3.024M	$12.47M
YoY Change	18.21%	4.38%	14.22%
Cash From Operating Activities	$2.434M	$17.51M	$18.64M
YoY Change	-135.47%	1618.16%	-332.98%
INVESTING ACTIVITIES
Capital Expenditures	$3.065M	$3.970M	$18.28M
YoY Change	-40.88%	-27.53%	6.98%
Acquisitions			$0.00
YoY Change			-100.0%
Other Investing Activities	-$516.0K	-$13.48M	-$1.585M
YoY Change	416.0%	-46.24%	-199.19%
Cash From Investing Activities	-$2.737M	-$17.45M	$7.639M
YoY Change	-108.07%	-42.88%	-111.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net			$1.717M
YoY Change			200.7%
Cash From Financing Activities	-$286.0K	566.0K	$59.13M
YoY Change	-100.85%	-96.14%	-2.66%
NET CHANGE
Cash From Operating Activities	$2.434M	17.51M	$18.64M
Cash From Investing Activities	-$2.737M	-17.45M	$7.639M
Cash From Financing Activities	-$286.0K	566.0K	$59.13M
Net Change In Cash	-$902.0K	623.0K	$85.83M
YoY Change	-101.48%	-104.2%	-628.75%
FREE CASH FLOW
Cash From Operating Activities	$2.434M	$17.51M	$18.64M
Capital Expenditures	$3.065M	$3.970M	$18.28M
Free Cash Flow	-$631.0K	$13.54M	$358.0K
YoY Change	-94.76%	-403.61%	-101.43%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	622812960	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41814768	shares
CY2023	trup	Reinsurance Trust Minimum Payment ReinsuranceTrustMinimumPayment	2000000	cad
CY2023	trup	Reinsurance Trust Payment Unearned Premium Percentage ReinsuranceTrustPaymentUnearnedPremiumPercentage	1.20
CY2023	trup	Reinsurance Paymentof Percentageof Canadian Claimsoutstanding ReinsurancePaymentofPercentageofCanadianClaimsoutstanding	0.20
CY2023Q4	trup	Reinsurance Trust Balance ReinsuranceTrustBalance	15700000	cad
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Seattle, Washington
CY2023	us-gaap	Revenues Revenues	1108605000	usd
CY2022	us-gaap	Revenues Revenues	905179000	usd
CY2021	us-gaap	Revenues Revenues	698991000	usd
CY2023	trup	Claims Expense ClaimsExpense	831055000	usd
CY2022	trup	Claims Expense ClaimsExpense	649737000	usd
CY2021	trup	Claims Expense ClaimsExpense	486062000	usd
CY2023	trup	Other Costof Services Sold OtherCostofServicesSold	146534000	usd
CY2022	trup	Other Costof Services Sold OtherCostofServicesSold	133257000	usd
CY2021	trup	Other Costof Services Sold OtherCostofServicesSold	108583000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	977589000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	594645000	usd
CY2023	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	21403000	usd
CY2022	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	25133000	usd
CY2021	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	16866000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60207000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39379000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31893000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	77372000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	89500000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	78647000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12474000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10921000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001371285
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41814768	shares
CY2021	us-gaap	Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List FairValueAssetRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2022	us-gaap	Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List FairValueAssetRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2023	us-gaap	Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List FairValueAssetRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	622812960	usd
CY2023Q4	trup	Reinsurance Trust Balance ReinsuranceTrustBalance	15700000	cad
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Seattle, Washington
CY2023	us-gaap	Revenues Revenues	1108605000	usd
CY2022	us-gaap	Revenues Revenues	905179000	usd
CY2021	us-gaap	Revenues Revenues	698991000	usd
CY2023	trup	Claims Expense ClaimsExpense	831055000	usd
CY2022	trup	Claims Expense ClaimsExpense	649737000	usd
CY2021	trup	Claims Expense ClaimsExpense	486062000	usd
CY2023	trup	Other Costof Services Sold OtherCostofServicesSold	146534000	usd
CY2021	trup	Other Costof Services Sold OtherCostofServicesSold	108583000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	977589000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	594645000	usd
CY2023	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	21403000	usd
CY2022	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	25133000	usd
CY2021	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	16866000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60207000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39379000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	77372000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	89500000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	78647000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12474000	usd
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	622812960	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41814768	shares
CY2023Q4	trup	Reinsurance Trust Balance ReinsuranceTrustBalance	15700000	cad
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Seattle, Washington
CY2023	us-gaap	Revenues Revenues	1108605000	usd
CY2022	us-gaap	Revenues Revenues	905179000	usd
CY2021	us-gaap	Revenues Revenues	698991000	usd
CY2023	trup	Claims Expense ClaimsExpense	831055000	usd
CY2022	trup	Claims Expense ClaimsExpense	649737000	usd
CY2021	trup	Claims Expense ClaimsExpense	486062000	usd
CY2023	trup	Other Costof Services Sold OtherCostofServicesSold	146534000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	977589000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	782994000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	594645000	usd
CY2023	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	21403000	usd
CY2022	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	25133000	usd
CY2021	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	16866000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60207000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39379000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31893000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	77372000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	89500000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	78647000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12474000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10921000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	171456000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	164933000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	139371000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-219000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-253000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-171000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40659000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-43001000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-35196000	usd
CY2023	us-gaap	Interest Expense InterestExpense	12077000	usd
CY2022	us-gaap	Interest Expense InterestExpense	4267000	usd
CY2021	us-gaap	Interest Expense InterestExpense	10000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7701000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3072000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45035000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44196000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35220000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	476000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	310000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35530000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41436882	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44693000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44672000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35530000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2712000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4412000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-496000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3992000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10921000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	171456000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	164933000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-219000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-253000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-171000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40659000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-43001000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-35196000	usd
CY2023	us-gaap	Interest Expense InterestExpense	12077000	usd
CY2021	us-gaap	Interest Expense InterestExpense	10000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7701000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3072000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45035000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44196000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	476000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	310000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35530000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41436882	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44693000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35530000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2712000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4412000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-496000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3992000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4966000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	502000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6704000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-9378000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37989000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54050000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35524000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147501000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65605000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	129667000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	156804000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1085000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	540000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	17022000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	14248000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	562089000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	469096000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	22963000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	19032000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	12866000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	7841000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103650000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90701000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18745000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24031000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11965000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	171456000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	164933000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-219000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-253000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-171000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-40659000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-43001000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-35196000	usd
CY2023	us-gaap	Interest Expense InterestExpense	12077000	usd
CY2022	us-gaap	Interest Expense InterestExpense	4267000	usd
CY2021	us-gaap	Interest Expense InterestExpense	10000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7701000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3072000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45035000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44196000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35220000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	476000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90701000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41436882	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44693000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44672000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35530000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4412000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-496000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3992000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	502000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6704000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-9378000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37989000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54050000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35524000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147501000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65605000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	129667000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	156804000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	540000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	267899000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	232439000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	14248000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	562089000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	469096000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	22963000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	19032000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	12866000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	7841000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103650000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18745000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24031000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18922000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4966000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	502000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6704000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-9378000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37989000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54050000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35524000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147501000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65605000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	129667000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	156804000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1085000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	540000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	267899000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	232439000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	17022000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	14248000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	562089000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	469096000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	22963000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	19032000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	12866000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	7841000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103650000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90701000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18745000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24031000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18922000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18943000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	43713000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	41983000	usd
CY2023Q4	us-gaap	Assets Assets	782948000	usd
CY2022Q4	us-gaap	Assets Assets	671627000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10505000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9471000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34052000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32616000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	63238000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	43734000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	235329000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	202692000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1350000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1103000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	344474000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	289616000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	127580000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	68354000	usd
CY2023Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	2685000	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	3392000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4487000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4968000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	479226000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18922000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18943000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	43713000	usd
CY2023Q4	us-gaap	Assets Assets	782948000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10505000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9471000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34052000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32616000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	63238000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	43734000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	235329000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	202692000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1350000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1103000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	344474000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	289616000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	127580000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	68354000	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	3392000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4487000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4968000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	479226000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	366330000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42887052	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41858866	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42041344	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41013158	shares
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	536108000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499694000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	403000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6301000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171562000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	16534000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	16534000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	303722000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	305297000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	782948000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18943000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	43713000	usd
CY2022Q4	us-gaap	Assets Assets	671627000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10505000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9471000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34052000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32616000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	63238000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	43734000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	235329000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	202692000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1350000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1103000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	344474000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	289616000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	127580000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	68354000	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	3392000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4487000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4968000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	479226000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	366330000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42887052	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41858866	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42041344	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41013158	shares
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	536108000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499694000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	403000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6301000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171562000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	16534000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	16534000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	303722000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	305297000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	782948000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	671627000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	339939000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1117000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	366330000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42887052	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41858866	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42041344	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41013158	shares
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	536108000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499694000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	403000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6301000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216255000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171562000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	16534000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	303722000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	305297000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	782948000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	671627000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	339939000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1117000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28902000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35530000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	332200000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2124000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35026000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	5755000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-9378000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	305297000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1118000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6704000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44693000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44693000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44672000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35530000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12474000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10921000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11965000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	33161000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	33393000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	671627000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	339939000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1117000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28902000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35530000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	332200000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2124000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35026000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44672000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	305297000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1118000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35296000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6704000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44693000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	303722000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44693000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44672000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35530000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12474000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10921000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11965000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	33161000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	33393000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	28226000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1347000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1051000	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1927000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35440000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	66982000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	66170000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5227000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3055000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1644000	usd

CY2023

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

Yes

CY2023

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2023

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2023

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2023

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2023

dei

Entity Small Business

EntitySmallBusiness

false

CY2023

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2023

dei

Icfr Auditor Attestation Flag

IcfrAuditorAttestationFlag

true

CY2023

dei

Document Fin Stmt Error Correction Flag

DocumentFinStmtErrorCorrectionFlag

false

CY2023

dei

Entity Shell Company

EntityShellCompany

false

CY2023Q2

dei

Entity Public Float

EntityPublicFloat

622812960

usd

CY2024Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

41814768

shares

CY2023

trup

Reinsurance Trust Minimum Payment

ReinsuranceTrustMinimumPayment

2000000

cad

CY2023

trup

Reinsurance Trust Payment Unearned Premium Percentage

ReinsuranceTrustPaymentUnearnedPremiumPercentage

1.20

CY2023

trup

Reinsurance Paymentof Percentageof Canadian Claimsoutstanding

ReinsurancePaymentofPercentageofCanadianClaimsoutstanding

0.20

CY2023Q4

trup

Reinsurance Trust Balance

ReinsuranceTrustBalance

15700000

cad

CY2023

dei

Auditor Firm

AuditorFirmId

42

CY2023

dei

Auditor Name

AuditorName

Ernst & Young LLP

CY2023

dei

Auditor Location

AuditorLocation

Seattle, Washington

CY2023

us-gaap

Revenues

1108605000

usd

CY2022

us-gaap

Revenues

905179000

usd

CY2021

us-gaap

Revenues

698991000

usd

CY2023

trup

Claims Expense

ClaimsExpense

831055000

usd

CY2022

trup

Claims Expense

ClaimsExpense

649737000

usd

CY2021

trup

Claims Expense

ClaimsExpense

486062000

usd

CY2023

trup

Other Costof Services Sold

OtherCostofServicesSold

146534000

usd

CY2022

trup

Other Costof Services Sold

OtherCostofServicesSold

133257000

usd

CY2021

trup

Other Costof Services Sold

OtherCostofServicesSold

108583000

usd

CY2023

us-gaap

Cost Of Revenue

CostOfRevenue

977589000

usd

CY2021

us-gaap

Cost Of Revenue

CostOfRevenue

594645000

usd

CY2023

trup

Technologyand Development Expense

TechnologyandDevelopmentExpense

21403000

usd

CY2022

trup

Technologyand Development Expense

TechnologyandDevelopmentExpense

25133000

usd

CY2021

trup

Technologyand Development Expense

TechnologyandDevelopmentExpense

16866000

usd

CY2023

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

60207000

usd

CY2022

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

39379000

usd

CY2021

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

31893000

usd

CY2023

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

77372000

usd

CY2022

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

89500000

usd

CY2021

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

78647000

usd

CY2023

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

12474000

usd

CY2022

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

10921000

usd

CY2023

dei

Entity Central Index Key

EntityCentralIndexKey

0001371285

CY2023

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2023

dei

Document Type

DocumentType

10-K

CY2023

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2023

CY2023

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

FY

CY2023

dei

Amendment Flag

AmendmentFlag

false

CY2024Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

41814768

shares

CY2021

us-gaap

Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List

FairValueAssetRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList

http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense

CY2022

us-gaap

Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List

FairValueAssetRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList

http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense

CY2023

us-gaap

Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List

FairValueAssetRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList

http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense

CY2023

dei

Document Annual Report

DocumentAnnualReport

true

CY2023

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

Yes

CY2023

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2023

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2023

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2023

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2023

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2023

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2023

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2023

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2023

dei

Entity Small Business

EntitySmallBusiness

false

CY2023

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2023

dei

Icfr Auditor Attestation Flag

IcfrAuditorAttestationFlag

true

CY2023

dei

Document Fin Stmt Error Correction Flag

DocumentFinStmtErrorCorrectionFlag

false

CY2023

dei

Entity Shell Company

EntityShellCompany

false

CY2023Q2

dei

Entity Public Float

EntityPublicFloat

622812960

usd

CY2023Q4

trup

Reinsurance Trust Balance

ReinsuranceTrustBalance

15700000

cad

CY2023

dei

Auditor Firm

AuditorFirmId

42

CY2023

dei

Auditor Name

AuditorName

Ernst & Young LLP

CY2023

dei

Auditor Location

AuditorLocation

Seattle, Washington

CY2023

us-gaap

Revenues

1108605000

usd

CY2022

us-gaap

Revenues

905179000

usd

CY2021

us-gaap

Revenues

698991000

usd

CY2023

trup

Claims Expense

ClaimsExpense

831055000

usd

CY2022

trup

Claims Expense

ClaimsExpense

649737000

usd

CY2021

trup

Claims Expense

ClaimsExpense

486062000

usd

CY2023

trup

Other Costof Services Sold

OtherCostofServicesSold

146534000

usd

CY2021

trup

Other Costof Services Sold

OtherCostofServicesSold

108583000

usd

CY2023

us-gaap

Cost Of Revenue

CostOfRevenue

977589000

usd

CY2021

us-gaap

Cost Of Revenue

CostOfRevenue

594645000

usd

CY2023

trup

Technologyand Development Expense

TechnologyandDevelopmentExpense

21403000

usd

CY2022

trup

Technologyand Development Expense

TechnologyandDevelopmentExpense

25133000

usd

CY2021

trup

Technologyand Development Expense

TechnologyandDevelopmentExpense

16866000

usd

CY2023

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

60207000

usd

CY2022

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

39379000

usd

CY2023

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

77372000

usd

CY2022

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

89500000

usd

CY2021

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

78647000

usd

CY2023

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

12474000

usd

CY2023

dei

Entity Small Business

EntitySmallBusiness

false

CY2023

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2023

dei

Icfr Auditor Attestation Flag

IcfrAuditorAttestationFlag

true

CY2023

dei

Document Fin Stmt Error Correction Flag

DocumentFinStmtErrorCorrectionFlag

false

CY2023

dei

Entity Shell Company

EntityShellCompany

false

CY2023Q2

dei

Entity Public Float

EntityPublicFloat

622812960

usd

CY2024Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

41814768

shares

CY2023Q4

trup

Reinsurance Trust Balance

ReinsuranceTrustBalance

15700000

cad

CY2023

dei

Auditor Firm

AuditorFirmId

42

CY2023

dei

Auditor Name

AuditorName

Ernst & Young LLP

CY2023

dei

Auditor Location

AuditorLocation

Seattle, Washington

CY2023

us-gaap

Revenues

1108605000

usd

CY2022

us-gaap

Revenues

905179000

usd

CY2021

us-gaap

Revenues

698991000

usd

CY2023

trup

Claims Expense

ClaimsExpense

831055000

usd

CY2022

trup

Claims Expense

ClaimsExpense

649737000

usd

CY2021

trup

Claims Expense

ClaimsExpense

486062000

usd

CY2023

trup

Other Costof Services Sold

OtherCostofServicesSold

146534000

usd

CY2023

us-gaap

Cost Of Revenue

CostOfRevenue

977589000

usd

CY2022

us-gaap

Cost Of Revenue

CostOfRevenue

782994000

usd

CY2021

us-gaap

Cost Of Revenue

CostOfRevenue

594645000

usd

CY2023

trup

Technologyand Development Expense

TechnologyandDevelopmentExpense

21403000

usd

CY2022

trup

Technologyand Development Expense

TechnologyandDevelopmentExpense

25133000

usd

CY2021

trup

Technologyand Development Expense

TechnologyandDevelopmentExpense

16866000

usd

CY2023

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

60207000

usd

CY2022

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

39379000

usd

CY2021

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

31893000

usd

CY2023

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

77372000

usd

CY2022

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

89500000

usd

CY2021

us-gaap

Selling And Marketing Expense

SellingAndMarketingExpense

78647000

usd

CY2023

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

12474000

usd

CY2022

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

10921000

usd

CY2023

us-gaap

Operating Expenses

OperatingExpenses

171456000

usd

CY2022

us-gaap

Operating Expenses

OperatingExpenses

164933000

usd

CY2021

us-gaap

Operating Expenses

OperatingExpenses

139371000

usd

CY2023

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-219000

usd

CY2022

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-253000

usd

CY2021

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-171000

usd

CY2023

us-gaap

Operating Income Loss

OperatingIncomeLoss

-40659000

usd

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

-43001000

usd

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

-35196000

usd

CY2023

us-gaap

Interest Expense

InterestExpense

12077000

usd

CY2022

us-gaap

Interest Expense

InterestExpense

4267000

usd

CY2021

us-gaap

Interest Expense

InterestExpense

10000

usd

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

7701000

usd

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3072000

usd

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-14000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-45035000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-44196000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-35220000

usd

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

476000

usd

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

310000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2023

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

41436882

shares

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44693000

usd

CY2022

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44672000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2023

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

2712000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-4412000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-496000

usd

CY2023

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

3992000

usd

CY2022

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

10921000

usd

CY2023

us-gaap

Operating Expenses

OperatingExpenses

171456000

usd

CY2022

us-gaap

Operating Expenses

OperatingExpenses

164933000

usd

CY2023

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-219000

usd

CY2022

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-253000

usd

CY2021

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-171000

usd

CY2023

us-gaap

Operating Income Loss

OperatingIncomeLoss

-40659000

usd

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

-43001000

usd

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

-35196000

usd

CY2023

us-gaap

Interest Expense

InterestExpense

12077000

usd

CY2021

us-gaap

Interest Expense

InterestExpense

10000

usd

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

7701000

usd

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3072000

usd

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-14000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-45035000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-44196000

usd

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

476000

usd

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

310000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2023

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

41436882

shares

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44693000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2023

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

2712000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-4412000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-496000

usd

CY2023

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

3992000

usd

CY2022

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

-4966000

usd

CY2021

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

502000

usd

CY2023

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6704000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-9378000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6000

usd

CY2023

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-37989000

usd

CY2022

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-54050000

usd

CY2021

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-35524000

usd

CY2023Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

147501000

usd

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

65605000

usd

CY2023Q4

us-gaap

Short Term Investments

ShortTermInvestments

129667000

usd

CY2022Q4

us-gaap

Short Term Investments

ShortTermInvestments

156804000

usd

CY2023Q4

us-gaap

Allowance For Doubtful Accounts Premiums And Other Receivables

AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables

1085000

usd

CY2022Q4

us-gaap

Allowance For Doubtful Accounts Premiums And Other Receivables

AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables

540000

usd

CY2023Q4

us-gaap

Prepaid Expense And Other Assets

PrepaidExpenseAndOtherAssets

17022000

usd

CY2022Q4

us-gaap

Prepaid Expense And Other Assets

PrepaidExpenseAndOtherAssets

14248000

usd

CY2023Q4

us-gaap

Assets Current

AssetsCurrent

562089000

usd

CY2022Q4

us-gaap

Assets Current

AssetsCurrent

469096000

usd

CY2023Q4

us-gaap

Restricted Cash And Cash Equivalents

RestrictedCashAndCashEquivalents

22963000

usd

CY2022Q4

us-gaap

Restricted Cash And Cash Equivalents

RestrictedCashAndCashEquivalents

19032000

usd

CY2023Q4

us-gaap

Marketable Securities Noncurrent

MarketableSecuritiesNoncurrent

12866000

usd

CY2022Q4

us-gaap

Marketable Securities Noncurrent

MarketableSecuritiesNoncurrent

7841000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

103650000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

90701000

usd

CY2023Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

18745000

usd

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

24031000

usd

CY2021

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

11965000

usd

CY2023

us-gaap

Operating Expenses

OperatingExpenses

171456000

usd

CY2022

us-gaap

Operating Expenses

OperatingExpenses

164933000

usd

CY2023

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-219000

usd

CY2022

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-253000

usd

CY2021

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-171000

usd

CY2023

us-gaap

Operating Income Loss

OperatingIncomeLoss

-40659000

usd

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

-43001000

usd

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

-35196000

usd

CY2023

us-gaap

Interest Expense

InterestExpense

12077000

usd

CY2022

us-gaap

Interest Expense

InterestExpense

4267000

usd

CY2021

us-gaap

Interest Expense

InterestExpense

10000

usd

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

7701000

usd

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3072000

usd

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-14000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-45035000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-44196000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-35220000

usd

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

476000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

90701000

usd

CY2023

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

41436882

shares

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44693000

usd

CY2022

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44672000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-4412000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-496000

usd

CY2023

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

3992000

usd

CY2021

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

502000

usd

CY2023

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6704000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-9378000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6000

usd

CY2023

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-37989000

usd

CY2022

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-54050000

usd

CY2021

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-35524000

usd

CY2023Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

147501000

usd

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

65605000

usd

CY2023Q4

us-gaap

Short Term Investments

ShortTermInvestments

129667000

usd

CY2022Q4

us-gaap

Short Term Investments

ShortTermInvestments

156804000

usd

CY2022Q4

us-gaap

Allowance For Doubtful Accounts Premiums And Other Receivables

AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables

540000

usd

CY2023Q4

us-gaap

Accounts And Other Receivables Net Current

AccountsAndOtherReceivablesNetCurrent

267899000

usd

CY2022Q4

us-gaap

Accounts And Other Receivables Net Current

AccountsAndOtherReceivablesNetCurrent

232439000

usd

CY2022Q4

us-gaap

Prepaid Expense And Other Assets

PrepaidExpenseAndOtherAssets

14248000

usd

CY2023Q4

us-gaap

Assets Current

AssetsCurrent

562089000

usd

CY2022Q4

us-gaap

Assets Current

AssetsCurrent

469096000

usd

CY2023Q4

us-gaap

Restricted Cash And Cash Equivalents

RestrictedCashAndCashEquivalents

22963000

usd

CY2022Q4

us-gaap

Restricted Cash And Cash Equivalents

RestrictedCashAndCashEquivalents

19032000

usd

CY2023Q4

us-gaap

Marketable Securities Noncurrent

MarketableSecuritiesNoncurrent

12866000

usd

CY2022Q4

us-gaap

Marketable Securities Noncurrent

MarketableSecuritiesNoncurrent

7841000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

103650000

usd

CY2023Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

18745000

usd

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

24031000

usd

CY2023Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

18922000

usd

CY2022

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

-4966000

usd

CY2021

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

502000

usd

CY2023

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6704000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-9378000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6000

usd

CY2023

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-37989000

usd

CY2022

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-54050000

usd

CY2021

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-35524000

usd

CY2023Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

147501000

usd

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

65605000

usd

CY2023Q4

us-gaap

Short Term Investments

ShortTermInvestments

129667000

usd

CY2022Q4

us-gaap

Short Term Investments

ShortTermInvestments

156804000

usd

CY2023Q4

us-gaap

Allowance For Doubtful Accounts Premiums And Other Receivables

AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables

1085000

usd

CY2022Q4

us-gaap

Allowance For Doubtful Accounts Premiums And Other Receivables

AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables

540000

usd

CY2023Q4

us-gaap

Accounts And Other Receivables Net Current

AccountsAndOtherReceivablesNetCurrent

267899000

usd

CY2022Q4

us-gaap

Accounts And Other Receivables Net Current

AccountsAndOtherReceivablesNetCurrent

232439000

usd

CY2023Q4

us-gaap

Prepaid Expense And Other Assets

PrepaidExpenseAndOtherAssets

17022000

usd

CY2022Q4

us-gaap

Prepaid Expense And Other Assets

PrepaidExpenseAndOtherAssets

14248000

usd

CY2023Q4

us-gaap

Assets Current

AssetsCurrent

562089000

usd

CY2022Q4

us-gaap

Assets Current

AssetsCurrent

469096000

usd

CY2023Q4

us-gaap

Restricted Cash And Cash Equivalents

RestrictedCashAndCashEquivalents

22963000

usd

CY2022Q4

us-gaap

Restricted Cash And Cash Equivalents

RestrictedCashAndCashEquivalents

19032000

usd

CY2023Q4

us-gaap

Marketable Securities Noncurrent

MarketableSecuritiesNoncurrent

12866000

usd

CY2022Q4

us-gaap

Marketable Securities Noncurrent

MarketableSecuritiesNoncurrent

7841000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

103650000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

90701000

usd

CY2023Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

18745000

usd

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

24031000

usd

CY2023Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

18922000

usd

CY2022Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

18943000

usd

CY2023Q4

us-gaap

Goodwill

43713000

usd

CY2022Q4

us-gaap

Goodwill

41983000

usd

CY2023Q4

us-gaap

Assets

782948000

usd

CY2022Q4

us-gaap

Assets

671627000

usd

CY2023Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

10505000

usd

CY2022Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

9471000

usd

CY2023Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

34052000

usd

CY2022Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

32616000

usd

CY2023Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

63238000

usd

CY2022Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

43734000

usd

CY2023Q4

us-gaap

Deferred Revenue Current

DeferredRevenueCurrent

235329000

usd

CY2022Q4

us-gaap

Deferred Revenue Current

DeferredRevenueCurrent

202692000

usd

CY2023Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1350000

usd

CY2022Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1103000

usd

CY2023Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

344474000

usd

CY2022Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

289616000

usd

CY2023Q4

us-gaap

Long Term Debt

LongTermDebt

127580000

usd

CY2022Q4

us-gaap

Long Term Debt

LongTermDebt

68354000

usd

CY2023Q4

us-gaap

Deferred Tax And Other Liabilities Noncurrent

DeferredTaxAndOtherLiabilitiesNoncurrent

2685000

usd

CY2022Q4

us-gaap

Deferred Tax And Other Liabilities Noncurrent

DeferredTaxAndOtherLiabilitiesNoncurrent

3392000

usd

CY2023Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

4487000

usd

CY2022Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

4968000

usd

CY2023Q4

us-gaap

Liabilities

479226000

usd

CY2023Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

18922000

usd

CY2022Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

18943000

usd

CY2023Q4

us-gaap

Goodwill

43713000

usd

CY2023Q4

us-gaap

Assets

782948000

usd

CY2023Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

10505000

usd

CY2022Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

9471000

usd

CY2023Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

34052000

usd

CY2022Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

32616000

usd

CY2023Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

63238000

usd

CY2022Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

43734000

usd

CY2023Q4

us-gaap

Deferred Revenue Current

DeferredRevenueCurrent

235329000

usd

CY2022Q4

us-gaap

Deferred Revenue Current

DeferredRevenueCurrent

202692000

usd

CY2023Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1350000

usd

CY2022Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1103000

usd

CY2023Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

344474000

usd

CY2022Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

289616000

usd

CY2023Q4

us-gaap

Long Term Debt

LongTermDebt

127580000

usd

CY2022Q4

us-gaap

Long Term Debt

LongTermDebt

68354000

usd

CY2022Q4

us-gaap

Deferred Tax And Other Liabilities Noncurrent

DeferredTaxAndOtherLiabilitiesNoncurrent

3392000

usd

CY2023Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

4487000

usd

CY2022Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

4968000

usd

CY2023Q4

us-gaap

Liabilities

479226000

usd

CY2022Q4

us-gaap

Liabilities

366330000

usd

CY2023Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.00001

CY2022Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.00001

CY2022Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

42887052

shares

CY2023Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

41858866

shares

CY2022Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

42041344

shares

CY2022Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

41013158

shares

CY2023Q4

us-gaap

Common Stock Value Outstanding

CommonStockValueOutstanding

0

usd

CY2022Q4

us-gaap

Common Stock Value Outstanding

CommonStockValueOutstanding

0

usd

CY2022Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.00001

CY2023Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.00001

CY2023Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

10000000

shares

CY2022Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

10000000

shares

CY2022Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2023Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2023Q4

us-gaap

Preferred Stock Value Outstanding

PreferredStockValueOutstanding

0

usd

CY2022Q4

us-gaap

Preferred Stock Value Outstanding

PreferredStockValueOutstanding

0

usd

CY2023Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

536108000

usd

CY2022Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

499694000

usd

CY2023Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

403000

usd

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-6301000

usd

CY2022Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-171562000

usd

CY2022Q4

us-gaap

Treasury Stock Common Shares

TreasuryStockCommonShares

1028186

shares

CY2023Q4

us-gaap

Treasury Stock Common Shares

TreasuryStockCommonShares

1028186

shares

CY2023Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

16534000

usd

CY2022Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

16534000

usd

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

303722000

usd

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

305297000

usd

CY2023Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

782948000

usd

CY2022Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

18943000

usd

CY2023Q4

us-gaap

Goodwill

43713000

usd

CY2022Q4

us-gaap

Assets

671627000

usd

CY2023Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

10505000

usd

CY2022Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

9471000

usd

CY2023Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

34052000

usd

CY2022Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

32616000

usd

CY2023Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

63238000

usd

CY2022Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

43734000

usd

CY2023Q4

us-gaap

Deferred Revenue Current

DeferredRevenueCurrent

235329000

usd

CY2022Q4

us-gaap

Deferred Revenue Current

DeferredRevenueCurrent

202692000

usd

CY2023Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1350000

usd

CY2022Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1103000

usd

CY2023Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

344474000

usd

CY2022Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

289616000

usd

CY2023Q4

us-gaap

Long Term Debt

LongTermDebt

127580000

usd

CY2022Q4

us-gaap

Long Term Debt

LongTermDebt

68354000

usd

CY2022Q4

us-gaap

Deferred Tax And Other Liabilities Noncurrent

DeferredTaxAndOtherLiabilitiesNoncurrent

3392000

usd

CY2023Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

4487000

usd

CY2022Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

4968000

usd

CY2023Q4

us-gaap

Liabilities

479226000

usd

CY2022Q4

us-gaap

Liabilities

366330000

usd

CY2023Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.00001

CY2022Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.00001

CY2022Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

42887052

shares

CY2023Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

41858866

shares

CY2022Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

42041344

shares

CY2022Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

41013158

shares

CY2023Q4

us-gaap

Common Stock Value Outstanding

CommonStockValueOutstanding

0

usd

CY2022Q4

us-gaap

Common Stock Value Outstanding

CommonStockValueOutstanding

0

usd

CY2022Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.00001

CY2023Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.00001

CY2023Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

10000000

shares

CY2022Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

10000000

shares

CY2022Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2022Q4

us-gaap

Preferred Stock Value Outstanding

PreferredStockValueOutstanding

0

usd

CY2023Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

536108000

usd

CY2022Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

499694000

usd

CY2023Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

403000

usd

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-6301000

usd

CY2022Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-171562000

usd

CY2022Q4

us-gaap

Treasury Stock Common Shares

TreasuryStockCommonShares

1028186

shares

CY2023Q4

us-gaap

Treasury Stock Common Shares

TreasuryStockCommonShares

1028186

shares

CY2023Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

16534000

usd

CY2022Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

16534000

usd

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

303722000

usd

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

305297000

usd

CY2023Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

782948000

usd

CY2022Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

671627000

usd

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

339939000

usd

CY2021

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

1117000

usd

CY2022Q4

us-gaap

Liabilities

366330000

usd

CY2023Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.00001

CY2022Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.00001

CY2022Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

42887052

shares

CY2023Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

41858866

shares

CY2022Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

42041344

shares

CY2022Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

41013158

shares

CY2023Q4

us-gaap

Common Stock Value Outstanding

CommonStockValueOutstanding

0

usd

CY2022Q4

us-gaap

Common Stock Value Outstanding

CommonStockValueOutstanding

0

usd

CY2022Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.00001

CY2023Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.00001

CY2023Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

10000000

shares

CY2022Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

10000000

shares

CY2022Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2022Q4

us-gaap

Preferred Stock Value Outstanding

PreferredStockValueOutstanding

0

usd

CY2023Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

536108000

usd

CY2022Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

499694000

usd

CY2023Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

403000

usd

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-6301000

usd

CY2023Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-216255000

usd

CY2022Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-171562000

usd

CY2022Q4

us-gaap

Treasury Stock Common Shares

TreasuryStockCommonShares

1028186

shares

CY2023Q4

us-gaap

Treasury Stock Common Shares

TreasuryStockCommonShares

1028186

shares

CY2022Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

16534000

usd

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

303722000

usd

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

305297000

usd

CY2023Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

782948000

usd

CY2022Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

671627000

usd

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

339939000

usd

CY2021

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

1117000

usd

CY2021

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

28902000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

332200000

usd

CY2022

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

2124000

usd

CY2022

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

35026000

usd

CY2022

us-gaap

Treasury Stock Value Acquired Cost Method

TreasuryStockValueAcquiredCostMethod

5755000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-9378000

usd

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

305297000

usd

CY2023

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

1118000

usd

CY2023

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6704000

usd

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44693000

usd

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44693000

usd

CY2022

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44672000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2023

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

12474000

usd

CY2022

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

10921000

usd

CY2021

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

11965000

usd

CY2023

us-gaap

Share Based Compensation

ShareBasedCompensation

33161000

usd

CY2022

us-gaap

Share Based Compensation

ShareBasedCompensation

33393000

usd

CY2022Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

671627000

usd

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

339939000

usd

CY2021

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

1117000

usd

CY2021

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

28902000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

332200000

usd

CY2022

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

2124000

usd

CY2022

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

35026000

usd

CY2022

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44672000

usd

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

305297000

usd

CY2023

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

1118000

usd

CY2023

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

35296000

usd

CY2023

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6704000

usd

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44693000

usd

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

303722000

usd

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44693000

usd

CY2022

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44672000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2023

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

12474000

usd

CY2022

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

10921000

usd

CY2021

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

11965000

usd

CY2023

us-gaap

Share Based Compensation

ShareBasedCompensation

33161000

usd

CY2022

us-gaap

Share Based Compensation

ShareBasedCompensation

33393000

usd

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

28226000

usd

CY2023

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

-1347000

usd

CY2022

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

-1051000

usd

CY2021

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

1927000

usd

CY2023

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

35440000

usd

CY2022

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

66982000

usd

CY2021

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

66170000

usd

CY2022

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

5227000

usd

CY2021

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

3055000

usd

CY2023

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

1644000

usd

CY2022

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

3136000

usd

CY2021

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

8796000

usd

CY2023

trup

Increase Decreasein Claims Reserveand Loss Adjustment

IncreaseDecreaseinClaimsReserveandLossAdjustment

19485000

usd

CY2022

trup

Increase Decreasein Claims Reserveand Loss Adjustment

IncreaseDecreaseinClaimsReserveandLossAdjustment

4227000

usd

CY2021

trup

Increase Decreasein Claims Reserveand Loss Adjustment

IncreaseDecreaseinClaimsReserveandLossAdjustment

10768000

usd

CY2023

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

32567000

usd

CY2022

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

56153000

usd

CY2021

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

54385000

usd

CY2023

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

18638000

usd

CY2022

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-8000000

usd

CY2021

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

7458000

usd

CY2023

us-gaap

Payments To Acquire Held To Maturity Securities

PaymentsToAcquireHeldToMaturitySecurities

165936000

usd

CY2022

us-gaap

Payments To Acquire Held To Maturity Securities

PaymentsToAcquireHeldToMaturitySecurities

273006000

usd

CY2021

us-gaap

Payments To Acquire Held To Maturity Securities

PaymentsToAcquireHeldToMaturitySecurities

95672000

usd

CY2023

us-gaap

Proceeds From Sale And Maturity Of Held To Maturity Securities

ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

190270000

usd

CY2022

us-gaap

Proceeds From Sale And Maturity Of Held To Maturity Securities

ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

239210000

usd

CY2021

us-gaap

Proceeds From Sale And Maturity Of Held To Maturity Securities

ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

57869000

usd

CY2023

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

usd

CY2022

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

15034000

usd

CY2021

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

28902000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

332200000

usd

CY2022

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

2124000

usd

CY2022

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

35026000

usd

CY2022

us-gaap

Treasury Stock Value Acquired Cost Method

TreasuryStockValueAcquiredCostMethod

5755000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-9378000

usd

CY2022

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44672000

usd

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

305297000

usd

CY2023

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

35296000

usd

CY2023

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

6704000

usd

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44693000

usd

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

303722000

usd

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44693000

usd

CY2022

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-44672000

usd

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-35530000

usd

CY2023

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

12474000

usd

CY2022

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

10921000

usd

CY2021

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

11965000

usd

CY2023

us-gaap

Share Based Compensation

ShareBasedCompensation

33161000

usd

CY2022

us-gaap

Share Based Compensation

ShareBasedCompensation

33393000

usd

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

28226000

usd

CY2023

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

-1347000

usd

CY2021

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

1927000

usd

CY2023

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

35440000

usd

CY2021

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

66170000

usd

CY2023

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

1907000

usd

CY2022

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

5227000

usd

CY2021

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

3055000

usd

CY2023

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

1644000

usd

CY2022

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

3136000

usd

CY2021

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

8796000

usd

CY2023

trup

Increase Decreasein Claims Reserveand Loss Adjustment

IncreaseDecreaseinClaimsReserveandLossAdjustment

19485000

usd

CY2022

trup

Increase Decreasein Claims Reserveand Loss Adjustment

IncreaseDecreaseinClaimsReserveandLossAdjustment

4227000

usd

CY2021

trup

Increase Decreasein Claims Reserveand Loss Adjustment

IncreaseDecreaseinClaimsReserveandLossAdjustment

10768000

usd

CY2023

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

32567000

usd

CY2021

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

54385000

usd

CY2023

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

18638000

usd

CY2022

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-8000000

usd

CY2021

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

7458000

usd

CY2023

us-gaap

Payments To Acquire Held To Maturity Securities

PaymentsToAcquireHeldToMaturitySecurities

165936000

usd

CY2022

us-gaap

Payments To Acquire Held To Maturity Securities

PaymentsToAcquireHeldToMaturitySecurities

273006000

usd

CY2021

us-gaap

Payments To Acquire Held To Maturity Securities

PaymentsToAcquireHeldToMaturitySecurities

95672000

usd

CY2023

us-gaap

Proceeds From Sale And Maturity Of Held To Maturity Securities

ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

190270000

usd

CY2022

us-gaap

Proceeds From Sale And Maturity Of Held To Maturity Securities

ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

239210000

usd

CY2021

us-gaap

Proceeds From Sale And Maturity Of Held To Maturity Securities

ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

57869000

usd

CY2023

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

usd

CY2022

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

15034000

usd

CY2021

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

usd

CY2023

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

18280000

usd

CY2021

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

12355000

usd

CY2023

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-1585000

usd

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

28226000

usd

CY2022

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

-1051000

usd

CY2021

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

1927000

usd

CY2023

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

35440000

usd

CY2022

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

66982000

usd

CY2021

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

66170000

usd

CY2023

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

1907000

usd

CY2022

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

5227000

usd

CY2021

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

3055000

usd

CY2023

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

1644000

usd

CY2022

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

3136000

usd

CY2021

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

8796000

usd

CY2023

trup

Increase Decreasein Claims Reserveand Loss Adjustment

IncreaseDecreaseinClaimsReserveandLossAdjustment

19485000

usd

CY2022

trup

Increase Decreasein Claims Reserveand Loss Adjustment

IncreaseDecreaseinClaimsReserveandLossAdjustment

4227000

usd

CY2021

trup

Increase Decreasein Claims Reserveand Loss Adjustment

IncreaseDecreaseinClaimsReserveandLossAdjustment

10768000

usd

CY2023

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

32567000

usd

CY2022

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

56153000

usd

CY2021

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

54385000

usd

CY2022

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-8000000

usd

CY2021

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

7458000

usd

CY2023

us-gaap

Payments To Acquire Held To Maturity Securities

PaymentsToAcquireHeldToMaturitySecurities

165936000

usd

CY2022

us-gaap

Payments To Acquire Held To Maturity Securities

PaymentsToAcquireHeldToMaturitySecurities

273006000

usd

CY2021

us-gaap

Payments To Acquire Held To Maturity Securities

PaymentsToAcquireHeldToMaturitySecurities

95672000

usd

CY2023

us-gaap

Proceeds From Sale And Maturity Of Held To Maturity Securities

ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

190270000

usd

CY2022

us-gaap

Proceeds From Sale And Maturity Of Held To Maturity Securities

ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

239210000

usd

CY2021

us-gaap

Proceeds From Sale And Maturity Of Held To Maturity Securities

ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

57869000

usd

CY2023

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

usd

CY2022

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

15034000

usd

CY2021

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

usd

CY2023

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

18280000

usd

CY2022

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

17088000

usd

CY2021

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

12355000

usd

CY2023

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-1585000

usd

CY2022

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

1598000

usd

CY2021

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

1755000

usd

CY2023

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

7639000

usd

CY2022

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-67516000

usd

CY2021

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-51913000

usd

CY2023

trup

Proceeds From Debt Financing

ProceedsFromDebtFinancing

60102000

usd

CY2022

trup

Proceeds From Debt Financing

ProceedsFromDebtFinancing

69138000

usd

CY2021

trup

Proceeds From Debt Financing

ProceedsFromDebtFinancing

0

usd

CY2022

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

571000

usd

CY2023

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

usd

CY2022

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

5755000

usd

CY2021

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

usd

CY2023

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

2655000

usd

CY2022

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

2290000

usd

CY2021

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

3607000

usd

CY2023

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

1536000

usd

CY2022

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

4359000

usd

CY2023

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-378000

usd

CY2022

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

0

usd

CY2021

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

0

usd

CY2021

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

usd

CY2023

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

18280000

usd

CY2022

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

17088000

usd

CY2021

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

12355000

usd

CY2023

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-1585000

usd

CY2022

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

1598000

usd

CY2021

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

1755000

usd

CY2023

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

7639000

usd

CY2022

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-67516000

usd

CY2021

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-51913000

usd

CY2023

trup

Proceeds From Debt Financing

ProceedsFromDebtFinancing

60102000

usd

CY2022

trup

Proceeds From Debt Financing

ProceedsFromDebtFinancing

69138000

usd

CY2021

trup

Proceeds From Debt Financing

ProceedsFromDebtFinancing

0

usd

CY2023

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1717000

usd

CY2022

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

571000

usd

CY2021

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

0

usd

CY2023

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

usd

CY2022

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

5755000

usd

CY2021

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

usd

CY2023

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

2655000

usd

CY2022

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

2290000

usd

CY2021

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

3607000

usd

CY2023

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

1536000

usd

CY2023

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-378000

usd

CY2022

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

0

usd

CY2021

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

0

usd

CY2023

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

59126000

usd

CY2022

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

60743000

usd

CY2022

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

-1459000

usd

CY2021

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

252000

usd

CY2023

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

85827000

usd

CY2022

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-16232000

usd

CY2021

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-45328000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

84637000

usd

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

100869000

usd

CY2020Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

146197000

usd

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

170464000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

84637000

usd

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

100869000

usd

CY2023

us-gaap

Income Taxes Paid

IncomeTaxesPaid

611000

usd

CY2022

us-gaap

Income Taxes Paid

IncomeTaxesPaid

2498000

usd

CY2021

us-gaap

Income Taxes Paid

IncomeTaxesPaid

282000

usd

CY2023

us-gaap

Interest Paid Net

InterestPaidNet

12100000

usd

CY2022

us-gaap

Interest Paid Net

InterestPaidNet

3353000

usd

CY2021

us-gaap

Interest Paid Net

InterestPaidNet

16000

usd

CY2023

us-gaap

Capital Expenditures Incurred But Not Yet Paid

CapitalExpendituresIncurredButNotYetPaid

887000

usd

CY2022

us-gaap

Capital Expenditures Incurred But Not Yet Paid

CapitalExpendituresIncurredButNotYetPaid

1324000

usd

CY2021

us-gaap

Capital Expenditures Incurred But Not Yet Paid

CapitalExpendituresIncurredButNotYetPaid

729000

usd

CY2023

us-gaap

Nature Of Operations

NatureOfOperations

Nature of Operations and Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs in the United States, Canada, Continental Europe, and Australia. The Company's data-driven, vertically-integrated approach enables the Company to provide pet owners with products that the Company believes are the highest value medical insurance, priced specifically for each pet’s unique characteristics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At times, cash on deposit may be in excess of the applicable federal deposit insurance corporation limits.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any cash account not held in trust for a third party that is contractually restricted to withdrawal or use to be restricted cash. The Company is required to maintain certain restricted cash balances to comply with insurance company regulations. As of December 31, 2023, the Company was in compliance with all requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts and Other Receivables</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Accounts and other receivables are comprised of trade receivables and other miscellaneous receivables and are carried at their estimated collectible amounts. Trade receivables are primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies, with monthly payment terms through the end of the twelve-month period. The Company had $249.8 million and $220.8 million accounts receivable associated with underwriting these policies as of December 31, 2023 and 2022, respectively. During the year ended December 31, 2023, the Company incurred a non-recurring $3.8 million settlement of accounts receivable due to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Acquisition Costs</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs certain costs, including premium taxes, enrollment-based bonuses, and referral fees that directly relate to the successful acquisition of new or renewal customer contracts. These costs are deferred and are included in prepaid expenses and other assets on the consolidated balance sheet and amortized over the related policy term to the applicable financial statement line item, either new pet acquisition expense or other cost of revenue. Deferred acquisition costs as of December 31, 2023 and 2022 were $7.4 million and $6.0 million, respectively. Amortized deferred acquisition costs classified within new pet acquisition expense amounted to $6.0 million, $4.9 million, and $4.7 million and amortized deferred acquisition costs classified within other cost of revenue amounted to $45.6 million, $33.9 million, and $30.5 million, for the years ended December 31, 2023, 2022, and 2021, respectively. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in investment grade fixed maturity securities of varying maturities. Available-for-sale securities are reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Held-to-maturity securities are reported at amortized cost. Premiums or discounts on fixed maturity securities are amortized or accreted over the life of the security and included in interest income. There were $0.3 million in realized gains and $0.9 million in realized losses on sales of fixed maturity securities during the year ended December 31, 2023, and no realized gains or losses on sales of fixed maturity securities during the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, the Company evaluates whether declines in fair value of its investments below carrying value are the result of expected credit losses. This evaluation includes the Company's ability and intent to hold these investments until recovery of carrying value occurs, including an evaluation of all available information relevant to the collectability of the security, including past events, current conditions, and reasonable and supportable forecasts. Expected credit losses are recorded as an allowance through other expense (income), net on the Company's consolidated statements of operations. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments, in addition to those presented in Note 8, Fair Value, include cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment, and Internal-Use Software</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment, and internal-use software primarily consists of building, land and land improvements, office equipment, internal-use software related to the Company’s website, and internal support systems. Internal-use software is capitalized during the application development stage of the project. Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the respective asset:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:195.75pt"><tr><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:15.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciable</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are not amortized. The Company reviews these assets for impairment at least annually or if indicators of potential impairment exist. Acquired finite-lived intangibles are amortized on a straight-line basis over the estimated useful lives of the assets. The Company has recognized no impairment loss on goodwill and indefinite-lived intangible assets for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairment</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets, are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured as the amount the asset's carrying value exceeds its fair value. The Company has recognized no impairment loss on long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserve for Veterinary Invoices</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. To determine the accrual, the Company makes assumptions based on its historical experience, including the number of veterinary invoices it expects to receive, the average cost of those veterinary invoices, the length of time between the date of the veterinary invoice and the date the Company receives it, the member's chosen deductible, and the Company's expected cost to process and administer the payments. As of each balance sheet date, the Company reevaluates its reserve and adjusts the estimate for new information.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue is primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies for which revenue is recognized pro-rata over the twelve-month policy period. Deferred revenue also consists of subscription fees received or billed in advance of the subscription services within the Company's subscription business. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue primarily from subscription fees and through underwriting policies for unaffiliated general agents. For the year ended December 31, 2023, premiums from policies sourced by general agents accounted for 34% of our total revenue, and one general agent sourced members whose premiums accounted for over 10% of our total revenue. Revenue is recognized pro-rata over the terms of the customer contracts.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Veterinary Invoice Expense</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Veterinary invoice expense includes the Company’s costs to review and pay veterinary invoices, administer the payments, and provide member services, and other operating expenses directly or indirectly related to this process. The Company also accrues for veterinary invoices that have been incurred but not yet received or paid and the estimated cost of processing these invoices. Veterinary invoice expense also includes amounts paid by unaffiliated general agents on our behalf, and an estimate of amounts incurred and not yet paid for the other business segment.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Cost of Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other cost of revenue for the subscription business segment includes direct and indirect member service expenses, Territory Partner renewal fees, credit card transaction fees and premium tax expenses. Other cost of revenue for the other business segment includes the commissions the Company pays to unaffiliated general agents and costs to administer the programs in the other business segment.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology and Development</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology and development expenses primarily consist of personnel costs and related expenses for the Company's technology staff, which includes information technology development and infrastructure support and third-party services. It also includes expenses associated with development of new products and offerings. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel costs and related expenses for the Company’s finance, actuarial, human resources, legal, regulatory, and general management functions, as well as facilities and professional services.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Pet Acquisition Expense</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New pet acquisition expense primarily consists of costs, including employee compensation, to educate veterinarians and consumers about the benefits of Trupanion, to generate leads and to convert leads into enrolled pets, as well as print, online and promotional advertising costs. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense (Income), Net</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, was $7.7 million, $3.1 million, and nil, including interest income of $9.0 million, $3.0 million, and $0.3 million offset by credit losses of $1.7 million, nil, and nil for the years ended December 31, 2023, 2022, and 2021, respectively. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred, with the exception of television advertisements, which are expensed the first time each advertisement is aired. Advertising costs amounted to $16.9 million, $25.5 million and $23.6 million, in the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to stock-based transactions, including employee and non-employee stock option awards, restricted stock awards, and restricted stock units, is measured and recognized in the financial statements based on fair value. The fair value of restricted stock awards and restricted stock units is the common stock price as of the measurement date. The fair value of stock options is estimated on the measurement date using the Black-Scholes option-pricing model that requires management to apply judgment and make estimates, including: </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company estimates the expected volatility based on the historical volatility of a representative group of publicly traded companies with similar characteristics to the Company, and its own historical volatility;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term for awards granted to employees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has based its expected term for awards issued to employees on the simplified method, as permitted by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options, restricted stock awards, and restricted stock units is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes forfeitures when they occur. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability approach for accounting and reporting income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases, operating loss, and tax credit carryforwards. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a tax rate change is recognized in the period that includes the enactment date. Valuation allowances are provided for when it is considered more likely than not that deferred tax assets will not be realized.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Penalties and interest are classified as a component of income taxes.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements are reported in U.S. dollars. Assets and liabilities denominated in foreign currencies were translated to U.S. dollars, the reporting currency, at the exchange rates in effect on the balance sheet date. Revenue and expenses denominated in foreign currencies were translated to U.S. dollars using a weighted average rate for the relevant reporting period. Cumulative translation adjustments of $(0.1) million, $(2.8) million, and $1.6 million were recorded in accumulated other comprehensive loss (income) as of December 31, 2023, 2022, and 2021, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings, total assets, total liabilities, or total shareholders' equity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Operations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2015, the Company formed a segregated account in Bermuda as part of Wyndham Insurance Company (SAC) Limited (WICL) and entered into a revised fronting and reinsurance arrangement with Omega General Insurance Company (Omega) to include its newly formed segregated account. The Company maintains all risk with the business written in Canada and consolidates the entity in its financial statements. Dividends are allowed subject to the Segregated Accounts Company Act of 2000, which allows for dividends only to the extent that the entity remains solvent and the value of its assets remain greater than the aggregate of its liabilities and its issued share capital and share premium accounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company’s Canadian business, all plans are written by Omega and the risk is assumed by the Company through a fronting and reinsurance agreement. Premiums are recognized and earned pro rata over the terms of the related customer contracts. Revenue recognized from the agreement in 2023, 2022, and 2021 was $167.6 million, $135.9 million and $112.0 million, respectively, and deferred revenue relating to this arrangement at December 31, 2023 and 2022 was $9.5 million and $6.4 million, respectively. Reinsurance revenue was 15%, 15%, and 16% of total revenue in 2023, 2022, and 2021, respectively. Cash designated for the purpose of paying claims related to this reinsurance agreement was $11.2 million and $7.2 million at December 31, 2023 and 2022, respectively. In addition, as required by the Office of the Superintendent of Financial Institutions regulations related to the Company’s reinsurance agreement with Omega, the Company is required to fund a Canadian Trust account with the greater of CAD $2.0 million or 120% of unearned Canadian premium plus 20% of outstanding Canadian claims, including all incurred but not reported claims. As of December 31, 2023, the account balance was CAD $15.7 million and the Company was in compliance with all requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not transferred any risk to third-party reinsurers.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents, investments, and debt. The Company manages its risk by investing cash equivalents and investment securities in money market instruments and securities of the U.S. government, U.S. government agencies and high-credit-quality issuers of debt securities.

CY2022

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

1598000

usd

CY2021

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

1755000

usd

CY2023

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

7639000

usd

CY2022

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-67516000

usd

CY2021

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-51913000

usd

CY2023

trup

Proceeds From Debt Financing

ProceedsFromDebtFinancing

60102000

usd

CY2022

trup

Proceeds From Debt Financing

ProceedsFromDebtFinancing

69138000

usd

CY2021

trup

Proceeds From Debt Financing

ProceedsFromDebtFinancing

0

usd

CY2023

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1717000

usd

CY2022

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

571000

usd

CY2021

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

0

usd

CY2023

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

usd

CY2022

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

5755000

usd

CY2021

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

usd

CY2023

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

2655000

usd

CY2022

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

2290000

usd

CY2021

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

3607000

usd

CY2023

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

1536000

usd

CY2022

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

4359000

usd

CY2021

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

4732000

usd

CY2023

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-378000

usd

CY2022

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

0

usd

CY2021

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

0

usd

CY2023

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

59126000

usd

CY2022

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

60743000

usd

CY2021

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-1125000

usd

CY2023

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

424000

usd

CY2022

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

-1459000

usd

CY2021

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

252000

usd

CY2023

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

85827000

usd

CY2022

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-16232000

usd

CY2021

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-45328000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

84637000

usd

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

100869000

usd

CY2020Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

146197000

usd

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

170464000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

84637000

usd

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

100869000

usd

CY2023

us-gaap

Income Taxes Paid

IncomeTaxesPaid

611000

usd

CY2022

us-gaap

Income Taxes Paid

IncomeTaxesPaid

2498000

usd

CY2021

us-gaap

Income Taxes Paid

IncomeTaxesPaid

282000

usd

CY2023

us-gaap

Interest Paid Net

InterestPaidNet

12100000

usd

CY2022

us-gaap

Interest Paid Net

InterestPaidNet

3353000

usd

CY2021

us-gaap

Interest Paid Net

InterestPaidNet

16000

usd

CY2023

us-gaap

Capital Expenditures Incurred But Not Yet Paid

CapitalExpendituresIncurredButNotYetPaid

887000

usd

CY2022

us-gaap

Capital Expenditures Incurred But Not Yet Paid

CapitalExpendituresIncurredButNotYetPaid

1324000

usd

CY2021

us-gaap

Capital Expenditures Incurred But Not Yet Paid

CapitalExpendituresIncurredButNotYetPaid

729000

usd

CY2023

us-gaap

Nature Of Operations

NatureOfOperations

Nature of Operations and Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs in the United States, Canada, Continental Europe, and Australia. The Company's data-driven, vertically-integrated approach enables the Company to provide pet owners with products that the Company believes are the highest value medical insurance, priced specifically for each pet’s unique characteristics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At times, cash on deposit may be in excess of the applicable federal deposit insurance corporation limits.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any cash account not held in trust for a third party that is contractually restricted to withdrawal or use to be restricted cash. The Company is required to maintain certain restricted cash balances to comply with insurance company regulations. As of December 31, 2023, the Company was in compliance with all requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts and Other Receivables</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Accounts and other receivables are comprised of trade receivables and other miscellaneous receivables and are carried at their estimated collectible amounts. Trade receivables are primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies, with monthly payment terms through the end of the twelve-month period. The Company had $249.8 million and $220.8 million accounts receivable associated with underwriting these policies as of December 31, 2023 and 2022, respectively. During the year ended December 31, 2023, the Company incurred a non-recurring $3.8 million settlement of accounts receivable due to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Acquisition Costs</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs certain costs, including premium taxes, enrollment-based bonuses, and referral fees that directly relate to the successful acquisition of new or renewal customer contracts. These costs are deferred and are included in prepaid expenses and other assets on the consolidated balance sheet and amortized over the related policy term to the applicable financial statement line item, either new pet acquisition expense or other cost of revenue. Deferred acquisition costs as of December 31, 2023 and 2022 were $7.4 million and $6.0 million, respectively. Amortized deferred acquisition costs classified within new pet acquisition expense amounted to $6.0 million, $4.9 million, and $4.7 million and amortized deferred acquisition costs classified within other cost of revenue amounted to $45.6 million, $33.9 million, and $30.5 million, for the years ended December 31, 2023, 2022, and 2021, respectively. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in investment grade fixed maturity securities of varying maturities. Available-for-sale securities are reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Held-to-maturity securities are reported at amortized cost. Premiums or discounts on fixed maturity securities are amortized or accreted over the life of the security and included in interest income. There were $0.3 million in realized gains and $0.9 million in realized losses on sales of fixed maturity securities during the year ended December 31, 2023, and no realized gains or losses on sales of fixed maturity securities during the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, the Company evaluates whether declines in fair value of its investments below carrying value are the result of expected credit losses. This evaluation includes the Company's ability and intent to hold these investments until recovery of carrying value occurs, including an evaluation of all available information relevant to the collectability of the security, including past events, current conditions, and reasonable and supportable forecasts. Expected credit losses are recorded as an allowance through other expense (income), net on the Company's consolidated statements of operations. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments, in addition to those presented in Note 8, Fair Value, include cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment, and Internal-Use Software</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment, and internal-use software primarily consists of building, land and land improvements, office equipment, internal-use software related to the Company’s website, and internal support systems. Internal-use software is capitalized during the application development stage of the project. Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the respective asset:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:195.75pt"><tr><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:15.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciable</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are not amortized. The Company reviews these assets for impairment at least annually or if indicators of potential impairment exist. Acquired finite-lived intangibles are amortized on a straight-line basis over the estimated useful lives of the assets. The Company has recognized no impairment loss on goodwill and indefinite-lived intangible assets for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairment</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets, are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured as the amount the asset's carrying value exceeds its fair value. The Company has recognized no impairment loss on long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserve for Veterinary Invoices</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. To determine the accrual, the Company makes assumptions based on its historical experience, including the number of veterinary invoices it expects to receive, the average cost of those veterinary invoices, the length of time between the date of the veterinary invoice and the date the Company receives it, the member's chosen deductible, and the Company's expected cost to process and administer the payments. As of each balance sheet date, the Company reevaluates its reserve and adjusts the estimate for new information.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue is primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies for which revenue is recognized pro-rata over the twelve-month policy period. Deferred revenue also consists of subscription fees received or billed in advance of the subscription services within the Company's subscription business. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue primarily from subscription fees and through underwriting policies for unaffiliated general agents. For the year ended December 31, 2023, premiums from policies sourced by general agents accounted for 34% of our total revenue, and one general agent sourced members whose premiums accounted for over 10% of our total revenue. Revenue is recognized pro-rata over the terms of the customer contracts.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Veterinary Invoice Expense</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Veterinary invoice expense includes the Company’s costs to review and pay veterinary invoices, administer the payments, and provide member services, and other operating expenses directly or indirectly related to this process. The Company also accrues for veterinary invoices that have been incurred but not yet received or paid and the estimated cost of processing these invoices. Veterinary invoice expense also includes amounts paid by unaffiliated general agents on our behalf, and an estimate of amounts incurred and not yet paid for the other business segment.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Cost of Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other cost of revenue for the subscription business segment includes direct and indirect member service expenses, Territory Partner renewal fees, credit card transaction fees and premium tax expenses. Other cost of revenue for the other business segment includes the commissions the Company pays to unaffiliated general agents and costs to administer the programs in the other business segment.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology and Development</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology and development expenses primarily consist of personnel costs and related expenses for the Company's technology staff, which includes information technology development and infrastructure support and third-party services. It also includes expenses associated with development of new products and offerings. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel costs and related expenses for the Company’s finance, actuarial, human resources, legal, regulatory, and general management functions, as well as facilities and professional services.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Pet Acquisition Expense</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New pet acquisition expense primarily consists of costs, including employee compensation, to educate veterinarians and consumers about the benefits of Trupanion, to generate leads and to convert leads into enrolled pets, as well as print, online and promotional advertising costs. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense (Income), Net</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, was $7.7 million, $3.1 million, and nil, including interest income of $9.0 million, $3.0 million, and $0.3 million offset by credit losses of $1.7 million, nil, and nil for the years ended December 31, 2023, 2022, and 2021, respectively. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred, with the exception of television advertisements, which are expensed the first time each advertisement is aired. Advertising costs amounted to $16.9 million, $25.5 million and $23.6 million, in the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to stock-based transactions, including employee and non-employee stock option awards, restricted stock awards, and restricted stock units, is measured and recognized in the financial statements based on fair value. The fair value of restricted stock awards and restricted stock units is the common stock price as of the measurement date. The fair value of stock options is estimated on the measurement date using the Black-Scholes option-pricing model that requires management to apply judgment and make estimates, including: </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company estimates the expected volatility based on the historical volatility of a representative group of publicly traded companies with similar characteristics to the Company, and its own historical volatility;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term for awards granted to employees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has based its expected term for awards issued to employees on the simplified method, as permitted by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options, restricted stock awards, and restricted stock units is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes forfeitures when they occur. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability approach for accounting and reporting income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases, operating loss, and tax credit carryforwards. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a tax rate change is recognized in the period that includes the enactment date. Valuation allowances are provided for when it is considered more likely than not that deferred tax assets will not be realized.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Penalties and interest are classified as a component of income taxes.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements are reported in U.S. dollars. Assets and liabilities denominated in foreign currencies were translated to U.S. dollars, the reporting currency, at the exchange rates in effect on the balance sheet date. Revenue and expenses denominated in foreign currencies were translated to U.S. dollars using a weighted average rate for the relevant reporting period. Cumulative translation adjustments of $(0.1) million, $(2.8) million, and $1.6 million were recorded in accumulated other comprehensive loss (income) as of December 31, 2023, 2022, and 2021, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings, total assets, total liabilities, or total shareholders' equity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Operations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2015, the Company formed a segregated account in Bermuda as part of Wyndham Insurance Company (SAC) Limited (WICL) and entered into a revised fronting and reinsurance arrangement with Omega General Insurance Company (Omega) to include its newly formed segregated account. The Company maintains all risk with the business written in Canada and consolidates the entity in its financial statements. Dividends are allowed subject to the Segregated Accounts Company Act of 2000, which allows for dividends only to the extent that the entity remains solvent and the value of its assets remain greater than the aggregate of its liabilities and its issued share capital and share premium accounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company’s Canadian business, all plans are written by Omega and the risk is assumed by the Company through a fronting and reinsurance agreement. Premiums are recognized and earned pro rata over the terms of the related customer contracts. Revenue recognized from the agreement in 2023, 2022, and 2021 was $167.6 million, $135.9 million and $112.0 million, respectively, and deferred revenue relating to this arrangement at December 31, 2023 and 2022 was $9.5 million and $6.4 million, respectively. Reinsurance revenue was 15%, 15%, and 16% of total revenue in 2023, 2022, and 2021, respectively. Cash designated for the purpose of paying claims related to this reinsurance agreement was $11.2 million and $7.2 million at December 31, 2023 and 2022, respectively. In addition, as required by the Office of the Superintendent of Financial Institutions regulations related to the Company’s reinsurance agreement with Omega, the Company is required to fund a Canadian Trust account with the greater of CAD $2.0 million or 120% of unearned Canadian premium plus 20% of outstanding Canadian claims, including all incurred but not reported claims. As of December 31, 2023, the account balance was CAD $15.7 million and the Company was in compliance with all requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not transferred any risk to third-party reinsurers.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents, investments, and debt. The Company manages its risk by investing cash equivalents and investment securities in money market instruments and securities of the U.S. government, U.S. government agencies and high-credit-quality issuers of debt securities.

CY2022Q4

us-gaap

Deferred Policy Acquisition Costs

DeferredPolicyAcquisitionCosts

6000000

usd

CY2023

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

59126000

usd

CY2021

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-1125000

usd

CY2023

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

424000

usd

CY2022

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

-1459000

usd

CY2021

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

252000

usd

CY2023

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

85827000

usd

CY2022

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-16232000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

84637000

usd

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

100869000

usd

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

170464000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

84637000

usd

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

100869000

usd

CY2023

us-gaap

Income Taxes Paid

IncomeTaxesPaid

611000

usd

CY2022

us-gaap

Income Taxes Paid

IncomeTaxesPaid

2498000

usd

CY2021

us-gaap

Income Taxes Paid

IncomeTaxesPaid

282000

usd

CY2023

us-gaap

Interest Paid Net

InterestPaidNet

12100000

usd

CY2022

us-gaap

Interest Paid Net

InterestPaidNet

3353000

usd

CY2021

us-gaap

Interest Paid Net

InterestPaidNet

16000

usd

CY2023

us-gaap

Capital Expenditures Incurred But Not Yet Paid

CapitalExpendituresIncurredButNotYetPaid

887000

usd

CY2022

us-gaap

Capital Expenditures Incurred But Not Yet Paid

CapitalExpendituresIncurredButNotYetPaid

1324000

usd

CY2021

us-gaap

Capital Expenditures Incurred But Not Yet Paid

CapitalExpendituresIncurredButNotYetPaid

729000

usd

CY2023

us-gaap

Nature Of Operations

NatureOfOperations

Nature of Operations and Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs in the United States, Canada, Continental Europe, and Australia. The Company's data-driven, vertically-integrated approach enables the Company to provide pet owners with products that the Company believes are the highest value medical insurance, priced specifically for each pet’s unique characteristics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At times, cash on deposit may be in excess of the applicable federal deposit insurance corporation limits.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any cash account not held in trust for a third party that is contractually restricted to withdrawal or use to be restricted cash. The Company is required to maintain certain restricted cash balances to comply with insurance company regulations. As of December 31, 2023, the Company was in compliance with all requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts and Other Receivables</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Accounts and other receivables are comprised of trade receivables and other miscellaneous receivables and are carried at their estimated collectible amounts. Trade receivables are primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies, with monthly payment terms through the end of the twelve-month period. The Company had $249.8 million and $220.8 million accounts receivable associated with underwriting these policies as of December 31, 2023 and 2022, respectively. During the year ended December 31, 2023, the Company incurred a non-recurring $3.8 million settlement of accounts receivable due to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Acquisition Costs</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs certain costs, including premium taxes, enrollment-based bonuses, and referral fees that directly relate to the successful acquisition of new or renewal customer contracts. These costs are deferred and are included in prepaid expenses and other assets on the consolidated balance sheet and amortized over the related policy term to the applicable financial statement line item, either new pet acquisition expense or other cost of revenue. Deferred acquisition costs as of December 31, 2023 and 2022 were $7.4 million and $6.0 million, respectively. Amortized deferred acquisition costs classified within new pet acquisition expense amounted to $6.0 million, $4.9 million, and $4.7 million and amortized deferred acquisition costs classified within other cost of revenue amounted to $45.6 million, $33.9 million, and $30.5 million, for the years ended December 31, 2023, 2022, and 2021, respectively. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in investment grade fixed maturity securities of varying maturities. Available-for-sale securities are reported at fair value with unrealized gains and losses included in accumulated other comprehensive income (loss). Held-to-maturity securities are reported at amortized cost. Premiums or discounts on fixed maturity securities are amortized or accreted over the life of the security and included in interest income. There were $0.3 million in realized gains and $0.9 million in realized losses on sales of fixed maturity securities during the year ended December 31, 2023, and no realized gains or losses on sales of fixed maturity securities during the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, the Company evaluates whether declines in fair value of its investments below carrying value are the result of expected credit losses. This evaluation includes the Company's ability and intent to hold these investments until recovery of carrying value occurs, including an evaluation of all available information relevant to the collectability of the security, including past events, current conditions, and reasonable and supportable forecasts. Expected credit losses are recorded as an allowance through other expense (income), net on the Company's consolidated statements of operations. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments, in addition to those presented in Note 8, Fair Value, include cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment, and Internal-Use Software</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment, and internal-use software primarily consists of building, land and land improvements, office equipment, internal-use software related to the Company’s website, and internal support systems. Internal-use software is capitalized during the application development stage of the project. Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the respective asset:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:195.75pt"><tr><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:15.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciable</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">years</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are not amortized. The Company reviews these assets for impairment at least annually or if indicators of potential impairment exist. Acquired finite-lived intangibles are amortized on a straight-line basis over the estimated useful lives of the assets. The Company has recognized no impairment loss on goodwill and indefinite-lived intangible assets for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairment</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets, are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured as the amount the asset's carrying value exceeds its fair value. The Company has recognized no impairment loss on long-lived assets, including property, equipment, internal-use software, and finite-lived intangible assets for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserve for Veterinary Invoices</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. To determine the accrual, the Company makes assumptions based on its historical experience, including the number of veterinary invoices it expects to receive, the average cost of those veterinary invoices, the length of time between the date of the veterinary invoice and the date the Company receives it, the member's chosen deductible, and the Company's expected cost to process and administer the payments. As of each balance sheet date, the Company reevaluates its reserve and adjusts the estimate for new information.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue is primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. These policies are typically annual policies for which revenue is recognized pro-rata over the twelve-month policy period. Deferred revenue also consists of subscription fees received or billed in advance of the subscription services within the Company's subscription business. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue primarily from subscription fees and through underwriting policies for unaffiliated general agents. For the year ended December 31, 2023, premiums from policies sourced by general agents accounted for 34% of our total revenue, and one general agent sourced members whose premiums accounted for over 10% of our total revenue. Revenue is recognized pro-rata over the terms of the customer contracts.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Veterinary Invoice Expense</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Veterinary invoice expense includes the Company’s costs to review and pay veterinary invoices, administer the payments, and provide member services, and other operating expenses directly or indirectly related to this process. The Company also accrues for veterinary invoices that have been incurred but not yet received or paid and the estimated cost of processing these invoices. Veterinary invoice expense also includes amounts paid by unaffiliated general agents on our behalf, and an estimate of amounts incurred and not yet paid for the other business segment.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Cost of Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other cost of revenue for the subscription business segment includes direct and indirect member service expenses, Territory Partner renewal fees, credit card transaction fees and premium tax expenses. Other cost of revenue for the other business segment includes the commissions the Company pays to unaffiliated general agents and costs to administer the programs in the other business segment.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology and Development</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology and development expenses primarily consist of personnel costs and related expenses for the Company's technology staff, which includes information technology development and infrastructure support and third-party services. It also includes expenses associated with development of new products and offerings. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel costs and related expenses for the Company’s finance, actuarial, human resources, legal, regulatory, and general management functions, as well as facilities and professional services.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Pet Acquisition Expense</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New pet acquisition expense primarily consists of costs, including employee compensation, to educate veterinarians and consumers about the benefits of Trupanion, to generate leads and to convert leads into enrolled pets, as well as print, online and promotional advertising costs. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense (Income), Net</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, was $7.7 million, $3.1 million, and nil, including interest income of $9.0 million, $3.0 million, and $0.3 million offset by credit losses of $1.7 million, nil, and nil for the years ended December 31, 2023, 2022, and 2021, respectively. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred, with the exception of television advertisements, which are expensed the first time each advertisement is aired. Advertising costs amounted to $16.9 million, $25.5 million and $23.6 million, in the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to stock-based transactions, including employee and non-employee stock option awards, restricted stock awards, and restricted stock units, is measured and recognized in the financial statements based on fair value. The fair value of restricted stock awards and restricted stock units is the common stock price as of the measurement date. The fair value of stock options is estimated on the measurement date using the Black-Scholes option-pricing model that requires management to apply judgment and make estimates, including: </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company estimates the expected volatility based on the historical volatility of a representative group of publicly traded companies with similar characteristics to the Company, and its own historical volatility;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term for awards granted to employees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has based its expected term for awards issued to employees on the simplified method, as permitted by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options, restricted stock awards, and restricted stock units is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes forfeitures when they occur. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability approach for accounting and reporting income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities, and their respective tax bases, operating loss, and tax credit carryforwards. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a tax rate change is recognized in the period that includes the enactment date. Valuation allowances are provided for when it is considered more likely than not that deferred tax assets will not be realized.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Penalties and interest are classified as a component of income taxes.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements are reported in U.S. dollars. Assets and liabilities denominated in foreign currencies were translated to U.S. dollars, the reporting currency, at the exchange rates in effect on the balance sheet date. Revenue and expenses denominated in foreign currencies were translated to U.S. dollars using a weighted average rate for the relevant reporting period. Cumulative translation adjustments of $(0.1) million, $(2.8) million, and $1.6 million were recorded in accumulated other comprehensive loss (income) as of December 31, 2023, 2022, and 2021, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings, total assets, total liabilities, or total shareholders' equity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Operations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2015, the Company formed a segregated account in Bermuda as part of Wyndham Insurance Company (SAC) Limited (WICL) and entered into a revised fronting and reinsurance arrangement with Omega General Insurance Company (Omega) to include its newly formed segregated account. The Company maintains all risk with the business written in Canada and consolidates the entity in its financial statements. Dividends are allowed subject to the Segregated Accounts Company Act of 2000, which allows for dividends only to the extent that the entity remains solvent and the value of its assets remain greater than the aggregate of its liabilities and its issued share capital and share premium accounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company’s Canadian business, all plans are written by Omega and the risk is assumed by the Company through a fronting and reinsurance agreement. Premiums are recognized and earned pro rata over the terms of the related customer contracts. Revenue recognized from the agreement in 2023, 2022, and 2021 was $167.6 million, $135.9 million and $112.0 million, respectively, and deferred revenue relating to this arrangement at December 31, 2023 and 2022 was $9.5 million and $6.4 million, respectively. Reinsurance revenue was 15%, 15%, and 16% of total revenue in 2023, 2022, and 2021, respectively. Cash designated for the purpose of paying claims related to this reinsurance agreement was $11.2 million and $7.2 million at December 31, 2023 and 2022, respectively. In addition, as required by the Office of the Superintendent of Financial Institutions regulations related to the Company’s reinsurance agreement with Omega, the Company is required to fund a Canadian Trust account with the greater of CAD $2.0 million or 120% of unearned Canadian premium plus 20% of outstanding Canadian claims, including all incurred but not reported claims. As of December 31, 2023, the account balance was CAD $15.7 million and the Company was in compliance with all requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not transferred any risk to third-party reinsurers.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents, investments, and debt. The Company manages its risk by investing cash equivalents and investment securities in money market instruments and securities of the U.S. government, U.S. government agencies and high-credit-quality issuers of debt securities.

CY2023Q4

trup

Accounts Receivable Unaffiliated General Agents

AccountsReceivableUnaffiliatedGeneralAgents

249800000

usd

CY2022Q4

trup

Accounts Receivable Unaffiliated General Agents

AccountsReceivableUnaffiliatedGeneralAgents

220800000

usd

CY2023

us-gaap

Allowance For Doubtful Accounts Receivable Write Offs

AllowanceForDoubtfulAccountsReceivableWriteOffs

3800000

usd

CY2023Q4

us-gaap

Deferred Policy Acquisition Costs

DeferredPolicyAcquisitionCosts

7400000

usd

CY2023

us-gaap

Use Of Estimates

UseOfEstimates

<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.

CY2023Q4

trup

Accounts Receivable Unaffiliated General Agents

AccountsReceivableUnaffiliatedGeneralAgents

249800000

usd

CY2022Q4

trup

Accounts Receivable Unaffiliated General Agents

AccountsReceivableUnaffiliatedGeneralAgents

220800000

usd

CY2023

us-gaap

Allowance For Doubtful Accounts Receivable Write Offs

AllowanceForDoubtfulAccountsReceivableWriteOffs

3800000

usd

CY2023Q4

us-gaap

Deferred Policy Acquisition Costs

DeferredPolicyAcquisitionCosts

7400000

usd

CY2022Q4

us-gaap

Deferred Policy Acquisition Costs

DeferredPolicyAcquisitionCosts

6000000

usd

CY2023

us-gaap

Use Of Estimates

UseOfEstimates

<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.

CY2023Q4

trup

Accounts Receivable Unaffiliated General Agents

AccountsReceivableUnaffiliatedGeneralAgents

249800000

usd

CY2022Q4

trup

Accounts Receivable Unaffiliated General Agents

AccountsReceivableUnaffiliatedGeneralAgents

220800000

usd

CY2023

us-gaap

Allowance For Doubtful Accounts Receivable Write Offs

AllowanceForDoubtfulAccountsReceivableWriteOffs

3800000

usd

CY2023Q4

us-gaap

Deferred Policy Acquisition Costs

DeferredPolicyAcquisitionCosts

7400000

usd

CY2022Q4

us-gaap

Deferred Policy Acquisition Costs

DeferredPolicyAcquisitionCosts

6000000

usd

CY2023

us-gaap

Debt Securities Available For Sale Realized Gain

DebtSecuritiesAvailableForSaleRealizedGain

300000

usd

CY2023

us-gaap

Debt Securities Available For Sale Realized Loss

DebtSecuritiesAvailableForSaleRealizedLoss

900000

usd

CY2021

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

0

usd

CY2022

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

0

usd

CY2023

us-gaap

Goodwill And Intangible Asset Impairment

GoodwillAndIntangibleAssetImpairment

0

usd

CY2022Q4

trup

Impairment Amount License Intangibles

ImpairmentAmountLicenseIntangibles

0

usd

CY2021Q4

trup

Impairment Amount License Intangibles

ImpairmentAmountLicenseIntangibles

0

usd

CY2023Q4

trup

Impairment Amount License Intangibles

ImpairmentAmountLicenseIntangibles

0

usd

CY2023

us-gaap

Debt Securities Available For Sale Realized Gain

DebtSecuritiesAvailableForSaleRealizedGain

300000

usd

CY2023

us-gaap

Debt Securities Available For Sale Realized Loss

DebtSecuritiesAvailableForSaleRealizedLoss

900000

usd

CY2021

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

0

usd

CY2022

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

0

usd

CY2023

us-gaap

Goodwill And Intangible Asset Impairment

GoodwillAndIntangibleAssetImpairment

0

usd

CY2022Q4

trup

Impairment Amount License Intangibles

ImpairmentAmountLicenseIntangibles

0

usd

CY2021Q4

trup

Impairment Amount License Intangibles

ImpairmentAmountLicenseIntangibles

0

usd

CY2023Q4

trup

Impairment Amount License Intangibles

ImpairmentAmountLicenseIntangibles

0

usd

CY2023

us-gaap

Debt Securities Available For Sale Realized Loss

DebtSecuritiesAvailableForSaleRealizedLoss

900000

usd

CY2021

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

0

usd

CY2022

us-gaap

Realized Investment Gains Losses

RealizedInvestmentGainsLosses

0

usd

CY2023

us-gaap

Goodwill And Intangible Asset Impairment

GoodwillAndIntangibleAssetImpairment

0

usd

CY2022Q4

trup

Impairment Amount License Intangibles

ImpairmentAmountLicenseIntangibles

0

usd

CY2021Q4

trup

Impairment Amount License Intangibles

ImpairmentAmountLicenseIntangibles

0

usd

CY2023Q4

trup

Impairment Amount License Intangibles

ImpairmentAmountLicenseIntangibles

0

usd

CY2023Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

35031000

usd

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

7700000

usd

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3100000

usd

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

7700000

usd

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3100000

usd

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

7700000

usd

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3100000

usd

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

0

usd

CY2022

us-gaap

Interest Income Other

InterestIncomeOther

3000000

usd

CY2021

us-gaap

Interest Income Other

InterestIncomeOther

300000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

1700000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

0

usd

CY2021Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

0

usd

CY2023

us-gaap

Advertising Expense

AdvertisingExpense

16900000

usd

CY2021

us-gaap

Advertising Expense

AdvertisingExpense

23600000

usd

CY2023Q4

trup

Deferred Revenuefrom Fronting Agreement

DeferredRevenuefromFrontingAgreement

9500000

usd

CY2022Q4

trup

Deferred Revenuefrom Fronting Agreement

DeferredRevenuefromFrontingAgreement

6400000

usd

CY2023

us-gaap

Reinsurance Retention Policy Reinsured Risk Percentage

ReinsuranceRetentionPolicyReinsuredRiskPercentage

0.15

CY2022

us-gaap

Reinsurance Retention Policy Reinsured Risk Percentage

ReinsuranceRetentionPolicyReinsuredRiskPercentage

0.15

CY2021

us-gaap

Reinsurance Retention Policy Reinsured Risk Percentage

ReinsuranceRetentionPolicyReinsuredRiskPercentage

0.16

CY2023Q4

trup

Cash Designatedfor Paying Reinsurance Claims

CashDesignatedforPayingReinsuranceClaims

11200000

usd

CY2022Q4

trup

Cash Designatedfor Paying Reinsurance Claims

CashDesignatedforPayingReinsuranceClaims

7200000

usd

CY2023

trup

Reinsurance Trust Minimum Payment

ReinsuranceTrustMinimumPayment

2000000

cad

CY2023

trup

Reinsurance Trust Payment Unearned Premium Percentage

ReinsuranceTrustPaymentUnearnedPremiumPercentage

1.20

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

0

usd

CY2023

us-gaap

Interest Income Other

InterestIncomeOther

9000000

usd

CY2022

us-gaap

Interest Income Other

InterestIncomeOther

3000000

usd

CY2021

us-gaap

Interest Income Other

InterestIncomeOther

300000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

1700000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

0

usd

CY2021Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

0

usd

CY2023

us-gaap

Advertising Expense

AdvertisingExpense

16900000

usd

CY2022

us-gaap

Advertising Expense

AdvertisingExpense

25500000

usd

CY2021

us-gaap

Advertising Expense

AdvertisingExpense

23600000

usd

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2800000

usd

CY2021Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

1600000

usd

CY2023

trup

Reinsurance Paymentof Percentageof Canadian Claimsoutstanding

ReinsurancePaymentofPercentageofCanadianClaimsoutstanding

0.20

CY2023Q4

trup

Reinsurance Trust Balance

ReinsuranceTrustBalance

15700000

cad

CY2023Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

16286000

usd

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

0

usd

CY2023

us-gaap

Interest Income Other

InterestIncomeOther

9000000

usd

CY2022

us-gaap

Interest Income Other

InterestIncomeOther

3000000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

1700000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

0

usd

CY2021Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

0

usd

CY2023

us-gaap

Advertising Expense

AdvertisingExpense

16900000

usd

CY2021

us-gaap

Advertising Expense

AdvertisingExpense

23600000

usd

CY2023Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-100000

usd

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2800000

usd

CY2021Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

1600000

usd

CY2023

trup

Premiums Recognizedfrom Fronting Agreement

PremiumsRecognizedfromFrontingAgreement

167600000

usd

CY2022

trup

Premiums Recognizedfrom Fronting Agreement

PremiumsRecognizedfromFrontingAgreement

135900000

usd

CY2021

trup

Premiums Recognizedfrom Fronting Agreement

PremiumsRecognizedfromFrontingAgreement

112000000

usd

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2800000

usd

CY2021Q4

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

1600000

usd

CY2021

trup

Premiums Recognizedfrom Fronting Agreement

PremiumsRecognizedfromFrontingAgreement

112000000

usd

CY2023Q4

trup

Deferred Revenuefrom Fronting Agreement

DeferredRevenuefromFrontingAgreement

9500000

usd

CY2022Q4

trup

Deferred Revenuefrom Fronting Agreement

DeferredRevenuefromFrontingAgreement

6400000

usd

CY2023

us-gaap

Reinsurance Retention Policy Reinsured Risk Percentage

ReinsuranceRetentionPolicyReinsuredRiskPercentage

0.15

CY2022

us-gaap

Reinsurance Retention Policy Reinsured Risk Percentage

ReinsuranceRetentionPolicyReinsuredRiskPercentage

0.15

CY2021

us-gaap

Reinsurance Retention Policy Reinsured Risk Percentage

ReinsuranceRetentionPolicyReinsuredRiskPercentage

0.16

CY2023Q4

trup

Cash Designatedfor Paying Reinsurance Claims

CashDesignatedforPayingReinsuranceClaims

11200000

usd

CY2022Q4

trup

Cash Designatedfor Paying Reinsurance Claims

CashDesignatedforPayingReinsuranceClaims

7200000

usd

CY2023

trup

Reinsurance Paymentof Percentageof Canadian Claimsoutstanding

ReinsurancePaymentofPercentageofCanadianClaimsoutstanding

0.20

CY2023Q4

trup

Reinsurance Trust Balance

ReinsuranceTrustBalance

15700000

cad

CY2022

trup

Premiums Recognizedfrom Fronting Agreement

PremiumsRecognizedfromFrontingAgreement

135900000

usd

CY2023Q4

trup

Deferred Revenuefrom Fronting Agreement

DeferredRevenuefromFrontingAgreement

9500000

usd

CY2023

us-gaap

Reinsurance Retention Policy Reinsured Risk Percentage

ReinsuranceRetentionPolicyReinsuredRiskPercentage

0.15

CY2022

us-gaap

Reinsurance Retention Policy Reinsured Risk Percentage

ReinsuranceRetentionPolicyReinsuredRiskPercentage

0.15

CY2021

us-gaap

Reinsurance Retention Policy Reinsured Risk Percentage

ReinsuranceRetentionPolicyReinsuredRiskPercentage

0.16

CY2023Q4

trup

Cash Designatedfor Paying Reinsurance Claims

CashDesignatedforPayingReinsuranceClaims

11200000

usd

CY2022Q4

trup

Cash Designatedfor Paying Reinsurance Claims

CashDesignatedforPayingReinsuranceClaims

7200000

usd

CY2023Q4

trup

Reinsurance Trust Balance

ReinsuranceTrustBalance

15700000

cad

CY2023

us-gaap

Concentration Risk Credit Risk

ConcentrationRiskCreditRisk

<div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents, investments, and debt. The Company manages its risk by investing cash equivalents and investment securities in money market instruments and securities of the U.S. government, U.S. government agencies and high-credit-quality issuers of debt securities.

CY2022

us-gaap

Goodwill Foreign Currency Translation Gain Loss

GoodwillForeignCurrencyTranslationGainLoss

-2885000

usd

CY2022Q4

us-gaap

Goodwill

41983000

usd

CY2023

us-gaap

Goodwill Foreign Currency Translation Gain Loss

GoodwillForeignCurrencyTranslationGainLoss

1730000

usd

CY2023

us-gaap

Concentration Risk Credit Risk

ConcentrationRiskCreditRisk

<div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents, investments, and debt. The Company manages its risk by investing cash equivalents and investment securities in money market instruments and securities of the U.S. government, U.S. government agencies and high-credit-quality issuers of debt securities.

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets

295000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

27000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles

5121000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities

1677000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities

1056000

usd

CY2023Q4

us-gaap

Goodwill

43713000

usd

CY2023Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2023Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Asset Acquired In Place Leases

FiniteLivedIntangibleAssetAcquiredInPlaceLeases

848000

usd

CY2023Q4

us-gaap

Finite Lived Trade Names Gross

FiniteLivedTradeNamesGross

1294000

usd

CY2023Q4

trup

Finite Lived Developed Technologies Gross

FiniteLivedDevelopedTechnologiesGross

17278000

usd

CY2023Q4

us-gaap

Finite Lived Customer Relationships Gross

FiniteLivedCustomerRelationshipsGross

8379000

usd

CY2023Q4

us-gaap

Finite Lived Patents Gross

FiniteLivedPatentsGross

2459000

usd

CY2023

us-gaap

Concentration Risk Credit Risk

ConcentrationRiskCreditRisk

<div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents, investments, and debt. The Company manages its risk by investing cash equivalents and investment securities in money market instruments and securities of the U.S. government, U.S. government agencies and high-credit-quality issuers of debt securities.

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets

295000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

27000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles

5121000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities

1677000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities

1056000

usd

CY2023Q4

us-gaap

Finite Lived Patents Gross

FiniteLivedPatentsGross

2459000

usd

CY2023Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

35031000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

16286000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

16286000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets

295000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

27000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles

5121000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities

1677000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities

1056000

usd

CY2023Q4

us-gaap

Construction In Progress Gross

ConstructionInProgressGross

34627000

usd

CY2022Q4

us-gaap

Construction In Progress Gross

ConstructionInProgressGross

21415000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

145738000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

127882000

usd

CY2023Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

42088000

usd

CY2022Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

37181000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

103650000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

90701000

usd

CY2023

us-gaap

Depreciation

6700000

usd

CY2022

us-gaap

Depreciation

6100000

usd

CY2021

us-gaap

Depreciation

7100000

usd

CY2022

us-gaap

Goodwill Acquired During Period

GoodwillAcquiredDuringPeriod

12159000

usd

CY2022Q4

us-gaap

Construction In Progress Gross

ConstructionInProgressGross

21415000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

145738000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

127882000

usd

CY2023Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

42088000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

103650000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

90701000

usd

CY2023

us-gaap

Depreciation

6700000

usd

CY2022

us-gaap

Depreciation

6100000

usd

CY2021

us-gaap

Depreciation

7100000

usd

CY2021Q4

us-gaap

Goodwill

32709000

usd

CY2022

us-gaap

Goodwill Acquired During Period

GoodwillAcquiredDuringPeriod

12159000

usd

CY2022

us-gaap

Goodwill Foreign Currency Translation Gain Loss

GoodwillForeignCurrencyTranslationGainLoss

-2885000

usd

CY2022Q4

us-gaap

Goodwill

41983000

usd

CY2023

us-gaap

Goodwill Foreign Currency Translation Gain Loss

GoodwillForeignCurrencyTranslationGainLoss

1730000

usd

CY2023Q4

us-gaap

Goodwill

43713000

usd

CY2023Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2023Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Asset Acquired In Place Leases

FiniteLivedIntangibleAssetAcquiredInPlaceLeases

848000

usd

CY2023Q4

us-gaap

Finite Lived Trade Names Gross

FiniteLivedTradeNamesGross

1294000

usd

CY2023Q4

trup

Finite Lived Developed Technologies Gross

FiniteLivedDevelopedTechnologiesGross

17278000

usd

CY2023Q4

us-gaap

Finite Lived Customer Relationships Gross

FiniteLivedCustomerRelationshipsGross

8379000

usd

CY2023Q4

us-gaap

Finite Lived Patents Gross

FiniteLivedPatentsGross

2459000

usd

CY2023Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

35031000

usd

CY2023Q4

us-gaap

Construction In Progress Gross

ConstructionInProgressGross

34627000

usd

CY2022Q4

us-gaap

Construction In Progress Gross

ConstructionInProgressGross

21415000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

145738000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

127882000

usd

CY2023Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

42088000

usd

CY2022Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

37181000

usd

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

103650000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

90701000

usd

CY2023

us-gaap

Depreciation

6700000

usd

CY2022

us-gaap

Depreciation

6100000

usd

CY2021

us-gaap

Depreciation

7100000

usd

CY2021Q4

us-gaap

Goodwill

32709000

usd

CY2022

us-gaap

Goodwill Acquired During Period

GoodwillAcquiredDuringPeriod

12159000

usd

CY2022

us-gaap

Goodwill Foreign Currency Translation Gain Loss

GoodwillForeignCurrencyTranslationGainLoss

-2885000

usd

CY2022Q4

us-gaap

Goodwill

41983000

usd

CY2023

us-gaap

Goodwill Foreign Currency Translation Gain Loss

GoodwillForeignCurrencyTranslationGainLoss

1730000

usd

CY2023Q4

us-gaap

Goodwill

43713000

usd

CY2023Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2023Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Asset Acquired In Place Leases

FiniteLivedIntangibleAssetAcquiredInPlaceLeases

848000

usd

CY2023Q4

us-gaap

Finite Lived Trade Names Gross

FiniteLivedTradeNamesGross

1294000

usd

CY2023Q4

trup

Finite Lived Developed Technologies Gross

FiniteLivedDevelopedTechnologiesGross

17278000

usd

CY2023Q4

us-gaap

Finite Lived Customer Relationships Gross

FiniteLivedCustomerRelationshipsGross

8379000

usd

CY2023Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

18745000

usd

CY2023

us-gaap

Acquired Finite Lived Intangible Assets Weighted Average Useful Life

AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

P2Y9M18D

CY2022Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2022Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Asset Acquired In Place Leases

FiniteLivedIntangibleAssetAcquiredInPlaceLeases

2959000

usd

CY2022Q4

trup

Finite Lived Developed Technologies Gross

FiniteLivedDevelopedTechnologiesGross

16770000

usd

CY2022Q4

us-gaap

Finite Lived Customer Relationships Gross

FiniteLivedCustomerRelationshipsGross

7980000

usd

CY2022Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

36478000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

12447000

usd

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

24031000

usd

CY2023Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4800000

usd

CY2023

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

5700000

usd

CY2022

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

4800000

usd

CY2021

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

4900000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

5345000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

4556000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

1482000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

1311000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

164000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense After Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

443000

usd

CY2023Q4

trup

Finite Lived Intangible Assets Total Expected Amortization Expense

FiniteLivedIntangibleAssetsTotalExpectedAmortizationExpense

13301000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities Within One Year Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

2408000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

90278000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost

92698000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount

HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount

25477000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Within One Year Fair Value

HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue

25483000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount

HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount

997000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value

HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

1005000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Single Maturity Date Amortized Cost Basis

HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis

26474000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Single Maturity Date Fair Value

HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue

26488000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Unrealized Loss Position

DebtSecuritiesAvailableForSaleUnrealizedLossPosition

300000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Unrealized Loss Position

DebtSecuritiesAvailableForSaleUnrealizedLossPosition

800000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

18900000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

200000

usd

CY2023Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

18745000

usd

CY2023

us-gaap

Acquired Finite Lived Intangible Assets Weighted Average Useful Life

AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

P2Y9M18D

CY2022Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2022Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Asset Acquired In Place Leases

FiniteLivedIntangibleAssetAcquiredInPlaceLeases

2959000

usd

CY2022Q4

us-gaap

Finite Lived Trade Names Gross

FiniteLivedTradeNamesGross

1228000

usd

CY2022Q4

us-gaap

Finite Lived Customer Relationships Gross

FiniteLivedCustomerRelationshipsGross

7980000

usd

CY2022Q4

us-gaap

Finite Lived Patents Gross

FiniteLivedPatentsGross

2768000

usd

CY2022Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

36478000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

12447000

usd

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

24031000

usd

CY2023Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4800000

usd

CY2023

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

5700000

usd

CY2022

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

4800000

usd

CY2021

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

4900000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

5345000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

4556000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

1482000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

1311000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

164000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense After Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

443000

usd

CY2023Q4

trup

Finite Lived Intangible Assets Total Expected Amortization Expense

FiniteLivedIntangibleAssetsTotalExpectedAmortizationExpense

13301000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities Within One Year Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

2420000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities Within One Year Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

2408000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

90278000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost

92698000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

93169000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount

HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount

25477000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Within One Year Fair Value

HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue

25483000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount

HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount

997000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value

HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

1005000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Single Maturity Date Fair Value

HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue

26488000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Unrealized Loss Position

DebtSecuritiesAvailableForSaleUnrealizedLossPosition

300000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Unrealized Loss Position

DebtSecuritiesAvailableForSaleUnrealizedLossPosition

800000

usd

CY2023Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

18745000

usd

CY2023

us-gaap

Acquired Finite Lived Intangible Assets Weighted Average Useful Life

AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

P2Y9M18D

CY2022Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2022Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4773000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Asset Acquired In Place Leases

FiniteLivedIntangibleAssetAcquiredInPlaceLeases

2959000

usd

CY2022Q4

us-gaap

Finite Lived Trade Names Gross

FiniteLivedTradeNamesGross

1228000

usd

CY2022Q4

trup

Finite Lived Developed Technologies Gross

FiniteLivedDevelopedTechnologiesGross

16770000

usd

CY2022Q4

us-gaap

Finite Lived Customer Relationships Gross

FiniteLivedCustomerRelationshipsGross

7980000

usd

CY2022Q4

us-gaap

Finite Lived Patents Gross

FiniteLivedPatentsGross

2768000

usd

CY2022Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

36478000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

12447000

usd

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

24031000

usd

CY2023Q4

us-gaap

Indefinite Lived License Agreements

IndefiniteLivedLicenseAgreements

4800000

usd

CY2023

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

5700000

usd

CY2022

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

4800000

usd

CY2021

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

4900000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

5345000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

4556000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

1482000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

1311000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

164000

usd

CY2023Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense After Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

443000

usd

CY2023Q4

trup

Finite Lived Intangible Assets Total Expected Amortization Expense

FiniteLivedIntangibleAssetsTotalExpectedAmortizationExpense

13301000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities Within One Year Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

2420000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities Within One Year Fair Value

AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

2408000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

90278000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities After One Through Five Years Fair Value

AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

90761000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost

AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost

92698000

usd

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

93169000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount

HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount

25477000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Within One Year Fair Value

HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue

25483000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount

HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount

997000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value

HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

1005000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Single Maturity Date Amortized Cost Basis

HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis

26474000

usd

CY2023Q4

us-gaap

Held To Maturity Securities Debt Maturities Single Maturity Date Fair Value

HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue

26488000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Unrealized Loss Position

DebtSecuritiesAvailableForSaleUnrealizedLossPosition

300000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Unrealized Loss Position

DebtSecuritiesAvailableForSaleUnrealizedLossPosition

800000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

18900000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

200000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

25900000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

100000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

0

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

76300000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

800000

usd

CY2023

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

114700000

usd

CY2022

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

43000000

usd

CY2021Q4

trup

Purchaseof Equity Interest

PurchaseofEquityInterest

7000000

usd

CY2023

us-gaap

Increase Decrease In Notes Receivables

IncreaseDecreaseInNotesReceivables

7000000

usd

CY2023Q4

trup

Financing Receivable Revolving Annual Increase

FinancingReceivableRevolvingAnnualIncrease

2000000

usd

CY2023

trup

Lineof Creditoutstandingbalance Variable Interest Entity

LineofCreditoutstandingbalanceVariableInterestEntity

4000000

usd

CY2023

trup

Servicesperformedfor Variable Interest Entity

ServicesperformedforVariableInterestEntity

400000

usd

CY2022

trup

Servicesperformedfor Variable Interest Entity

ServicesperformedforVariableInterestEntity

800000

usd

CY2023Q4

trup

Commitmentto Contribute Capital

CommitmenttoContributeCapital

2200000

aud

CY2023

us-gaap

Payments To Acquire Interest In Joint Venture

PaymentsToAcquireInterestInJointVenture

1300000

usd

CY2023Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

5326000

usd

CY2023Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

188745000

usd

CY2022Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

4115000

usd

CY2022Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

113730000

usd

CY2023Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

5300000

usd

CY2022Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

4100000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

18900000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

25900000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

100000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

0

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

76300000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

800000

usd

CY2023

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

114700000

usd

CY2022

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

43000000

usd

CY2021Q4

trup

Purchaseof Equity Interest

PurchaseofEquityInterest

7000000

usd

CY2023

us-gaap

Increase Decrease In Notes Receivables

IncreaseDecreaseInNotesReceivables

7000000

usd

CY2023Q4

trup

Financing Receivable Revolving Annual Increase

FinancingReceivableRevolvingAnnualIncrease

2000000

usd

CY2023

trup

Lineof Creditoutstandingbalance Variable Interest Entity

LineofCreditoutstandingbalanceVariableInterestEntity

4000000

usd

CY2022

trup

Lineof Creditoutstandingbalance Variable Interest Entity

LineofCreditoutstandingbalanceVariableInterestEntity

6300000

usd

CY2023

trup

Servicesperformedfor Variable Interest Entity

ServicesperformedforVariableInterestEntity

400000

usd

CY2022

trup

Servicesperformedfor Variable Interest Entity

ServicesperformedforVariableInterestEntity

800000

usd

CY2023Q4

trup

Commitmentto Contribute Capital

CommitmenttoContributeCapital

2200000

aud

CY2023

us-gaap

Payments To Acquire Interest In Joint Venture

PaymentsToAcquireInterestInJointVenture

1300000

usd

CY2023Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

5326000

usd

CY2023Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

188745000

usd

CY2022Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

4115000

usd

CY2022Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

113730000

usd

CY2023Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

5300000

usd

CY2022Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

4100000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

25900000

usd

CY2023Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

100000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

0

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

76300000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

800000

usd

CY2023

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

114700000

usd

CY2022

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

43000000

usd

CY2021Q4

trup

Purchaseof Equity Interest

PurchaseofEquityInterest

7000000

usd

CY2023

us-gaap

Increase Decrease In Notes Receivables

IncreaseDecreaseInNotesReceivables

7000000

usd

CY2023Q4

trup

Financing Receivable Revolving Annual Increase

FinancingReceivableRevolvingAnnualIncrease

2000000

usd

CY2023

trup

Lineof Creditoutstandingbalance Variable Interest Entity

LineofCreditoutstandingbalanceVariableInterestEntity

4000000

usd

CY2022

trup

Lineof Creditoutstandingbalance Variable Interest Entity

LineofCreditoutstandingbalanceVariableInterestEntity

6300000

usd

CY2023

trup

Servicesperformedfor Variable Interest Entity

ServicesperformedforVariableInterestEntity

400000

usd

CY2022

trup

Servicesperformedfor Variable Interest Entity

ServicesperformedforVariableInterestEntity

800000

usd

CY2023Q4

trup

Commitmentto Contribute Capital

CommitmenttoContributeCapital

2200000

aud

CY2023

us-gaap

Payments To Acquire Interest In Joint Venture

PaymentsToAcquireInterestInJointVenture

1300000

usd

CY2023Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

5326000

usd

CY2023Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

188745000

usd

CY2022Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

4115000

usd

CY2022Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

113730000

usd

CY2023Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

5300000

usd

CY2022Q4

us-gaap

Noncontrolling Interest In Variable Interest Entity

NoncontrollingInterestInVariableInterestEntity

4100000

usd

CY2021

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

493000

usd

CY2022

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-4327000

usd

CY2023

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

2885000

usd

CY2023

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded

-1674000

usd

CY2023Q4

us-gaap

Notes Receivable Fair Value Disclosure

NotesReceivableFairValueDisclosure

6800000

usd

CY2022Q4

us-gaap

Notes Receivable Fair Value Disclosure

NotesReceivableFairValueDisclosure

9300000

usd

CY2023

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subscription</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veterinary invoices during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,799)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,411)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total veterinary invoice expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,001 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,739 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,896 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,543 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,407 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unfavorable development on veterinary invoice reserves for the subscription business segment of $2.8 million for the year ended December 31, 2023, favorable development on veterinary invoice reserves of $2.8 million for the year ended December 31, 2022, and favorable development on veterinary invoice reserves of $1.4 million for the year ended December 31, 2021, all of which were the result of ongoing analysis of recent payment trends. </span></div><div style="margin-top:4pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the changes in total liability for the Company's other business segment (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,004 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veterinary invoices during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total veterinary invoice expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,899 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,780 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unfavorable development on veterinary invoice reserves for the other business segment of $0.5 million for the year ended December 31, 2023, unfavorable development on veterinary invoice reserves of $1.1 million for the year ended December 31, 2022, and favorable development on veterinary invoice reserves of $0.2 million for the year ended December 31, 2021, all of which were the result of ongoing analysis of recent payment trends.</span></div>

CY2023

us-gaap

Line Of Credit Facility Initiation Date1

LineOfCreditFacilityInitiationDate1

2022-03-25

CY2023Q4

us-gaap

Line Of Credit Facility Maximum Borrowing Capacity

LineOfCreditFacilityMaximumBorrowingCapacity

150000000

usd

CY2023Q4

us-gaap

Debt Instrument Interest Rate Stated Percentage

DebtInstrumentInterestRateStatedPercentage

0.105

CY2023Q4

us-gaap

Deferred Finance Costs Gross

DeferredFinanceCostsGross

5900000

usd

CY2023

us-gaap

Line Of Credit Facility Expiration Date1

LineOfCreditFacilityExpirationDate1

2027-03-25

CY2023Q4

trup

Line Of Credit Facility Periodic Payment Principal Percentage

LineOfCreditFacilityPeriodicPaymentPrincipalPercentage

0.0025

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Two

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

1350000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Three

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

1350000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Four

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

72113000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

57125000

usd

CY2023Q4

us-gaap

Line Of Credit

LineOfCredit

133288000

usd

CY2021

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

493000

usd

CY2022

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-4327000

usd

CY2023

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

2885000

usd

CY2023

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded

-1674000

usd

CY2023Q4

us-gaap

Notes Receivable Fair Value Disclosure

NotesReceivableFairValueDisclosure

6800000

usd

CY2022Q4

us-gaap

Notes Receivable Fair Value Disclosure

NotesReceivableFairValueDisclosure

9300000

usd

CY2023

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subscription</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veterinary invoices during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,799)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,411)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total veterinary invoice expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,001 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,739 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,896 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,543 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,407 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unfavorable development on veterinary invoice reserves for the subscription business segment of $2.8 million for the year ended December 31, 2023, favorable development on veterinary invoice reserves of $2.8 million for the year ended December 31, 2022, and favorable development on veterinary invoice reserves of $1.4 million for the year ended December 31, 2021, all of which were the result of ongoing analysis of recent payment trends. </span></div><div style="margin-top:4pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the changes in total liability for the Company's other business segment (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,004 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veterinary invoices during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total veterinary invoice expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,899 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,780 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unfavorable development on veterinary invoice reserves for the other business segment of $0.5 million for the year ended December 31, 2023, unfavorable development on veterinary invoice reserves of $1.1 million for the year ended December 31, 2022, and favorable development on veterinary invoice reserves of $0.2 million for the year ended December 31, 2021, all of which were the result of ongoing analysis of recent payment trends.</span></div>

CY2023

us-gaap

Line Of Credit Facility Initiation Date1

LineOfCreditFacilityInitiationDate1

2022-03-25

CY2023Q4

us-gaap

Line Of Credit Facility Maximum Borrowing Capacity

LineOfCreditFacilityMaximumBorrowingCapacity

150000000

usd

CY2023Q4

us-gaap

Debt Instrument Interest Rate Stated Percentage

DebtInstrumentInterestRateStatedPercentage

0.105

CY2023Q4

us-gaap

Deferred Finance Costs Gross

DeferredFinanceCostsGross

5900000

usd

CY2023

us-gaap

Line Of Credit Facility Expiration Date1

LineOfCreditFacilityExpirationDate1

2027-03-25

CY2023Q4

trup

Line Of Credit Facility Periodic Payment Principal Percentage

LineOfCreditFacilityPeriodicPaymentPrincipalPercentage

0.0025

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Next Twelve Months

LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

1350000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Two

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

1350000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Three

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

1350000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

57125000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal After Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

0

usd

CY2023Q4

us-gaap

Line Of Credit

LineOfCredit

133288000

usd

CY2021

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

493000

usd

CY2022

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-4327000

usd

CY2023

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

2885000

usd

CY2023

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded

-1674000

usd

CY2023Q4

us-gaap

Notes Receivable Fair Value Disclosure

NotesReceivableFairValueDisclosure

6800000

usd

CY2022Q4

us-gaap

Notes Receivable Fair Value Disclosure

NotesReceivableFairValueDisclosure

9300000

usd

CY2023

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subscription</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veterinary invoices during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,799)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,411)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total veterinary invoice expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,001 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,739 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,896 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,543 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,407 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unfavorable development on veterinary invoice reserves for the subscription business segment of $2.8 million for the year ended December 31, 2023, favorable development on veterinary invoice reserves of $2.8 million for the year ended December 31, 2022, and favorable development on veterinary invoice reserves of $1.4 million for the year ended December 31, 2021, all of which were the result of ongoing analysis of recent payment trends. </span></div><div style="margin-top:4pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the changes in total liability for the Company's other business segment (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,004 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veterinary invoices during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total veterinary invoice expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid during the period related to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,899 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,780 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unfavorable development on veterinary invoice reserves for the other business segment of $0.5 million for the year ended December 31, 2023, unfavorable development on veterinary invoice reserves of $1.1 million for the year ended December 31, 2022, and favorable development on veterinary invoice reserves of $0.2 million for the year ended December 31, 2021, all of which were the result of ongoing analysis of recent payment trends.</span></div>

CY2023

us-gaap

Line Of Credit Facility Initiation Date1

LineOfCreditFacilityInitiationDate1

2022-03-25

CY2023Q4

us-gaap

Line Of Credit Facility Maximum Borrowing Capacity

LineOfCreditFacilityMaximumBorrowingCapacity

150000000

usd

CY2023Q4

us-gaap

Debt Instrument Interest Rate Stated Percentage

DebtInstrumentInterestRateStatedPercentage

0.105

CY2023Q4

us-gaap

Deferred Finance Costs Gross

DeferredFinanceCostsGross

5900000

usd

CY2023

us-gaap

Line Of Credit Facility Expiration Date1

LineOfCreditFacilityExpirationDate1

2027-03-25

CY2023Q4

trup

Line Of Credit Facility Periodic Payment Principal Percentage

LineOfCreditFacilityPeriodicPaymentPrincipalPercentage

0.0025

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Next Twelve Months

LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

1350000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Two

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

1350000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Three

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

1350000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Four

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

72113000

usd

CY2023Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

57125000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

408970

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

14.09

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

6715000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

6715000

usd

CY2023

trup

Sharebased Compensation Arrangementby Sharebased Payment Award Capitalized Cost

SharebasedCompensationArrangementbySharebasedPaymentAwardCapitalizedCost

2135000

usd

CY2022

trup

Sharebased Compensation Arrangementby Sharebased Payment Award Capitalized Cost

SharebasedCompensationArrangementbySharebasedPaymentAwardCapitalizedCost

1633000

usd

CY2021

trup

Sharebased Compensation Arrangementby Sharebased Payment Award Capitalized Cost

SharebasedCompensationArrangementbySharebasedPaymentAwardCapitalizedCost

676000

usd

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1

SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1

35296000

usd

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost

ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost

4800000

usd

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

1459290

shares

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

9.93

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

160200000

usd

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2021

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0

CY2021

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

647164

shares

CY2021

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

5.59

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

58200000

usd

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

4921

shares

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

13.66

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

807205

shares

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

13.39

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

95765000

usd

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2022

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0

CY2022

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

174721

shares

CY2022

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

12.82

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

10931000

usd

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

2834

shares

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

18.87

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

629650

shares

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0

CY2023

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

213848

shares

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

12.47

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

3720000

usd

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

6832

shares

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

12.80

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

408970

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

14.09

CY2023

trup

Sharebased Compensation Arrangementby Sharebased Payment Award Capitalized Cost

SharebasedCompensationArrangementbySharebasedPaymentAwardCapitalizedCost

2135000

usd

CY2022

trup

Sharebased Compensation Arrangementby Sharebased Payment Award Capitalized Cost

SharebasedCompensationArrangementbySharebasedPaymentAwardCapitalizedCost

1633000

usd

CY2021

trup

Sharebased Compensation Arrangementby Sharebased Payment Award Capitalized Cost

SharebasedCompensationArrangementbySharebasedPaymentAwardCapitalizedCost

676000

usd

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1

SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1

35296000

usd

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1

SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1

35026000

usd

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1

SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1

28902000

usd

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost

ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost

4800000

usd

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

1459290

shares

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

9.93

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

160200000

usd

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2021

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0

CY2021

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

647164

shares

CY2021

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

5.59

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

4921

shares

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

13.66

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

807205

shares

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

13.39

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

95765000

usd

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2022

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0

CY2022

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

174721

shares

CY2022

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

12.82

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

10931000

usd

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

2834

shares

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

18.87

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

629650

shares

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

13.53

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

21410000

usd

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0

CY2023

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

213848

shares

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

12.47

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

3720000

usd

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

6832

shares

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

12.80

CY2023

trup

Sharebased Compensation Arrangementby Sharebased Payment Award Capitalized Cost

SharebasedCompensationArrangementbySharebasedPaymentAwardCapitalizedCost

2135000

usd

CY2022

trup

Sharebased Compensation Arrangementby Sharebased Payment Award Capitalized Cost

SharebasedCompensationArrangementbySharebasedPaymentAwardCapitalizedCost

1633000

usd

CY2021

trup

Sharebased Compensation Arrangementby Sharebased Payment Award Capitalized Cost

SharebasedCompensationArrangementbySharebasedPaymentAwardCapitalizedCost

676000

usd

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1

SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1

35296000

usd

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1

SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1

35026000

usd

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1

SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1

28902000

usd

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost

ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost

4800000

usd

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

1459290

shares

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

9.93

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

160200000

usd

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2021

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0

CY2021

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

647164

shares

CY2021

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

5.59

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

13.66

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

807205

shares

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

13.39

CY2022

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

174721

shares

CY2022

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

12.82

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

10931000

usd

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

2834

shares

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

18.87

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

629650

shares

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

13.53

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

21410000

usd

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0

CY2023

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

213848

shares

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

12.47

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

3720000

usd

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

6832

shares

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

12.80

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

408970

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

14.09

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

6715000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

408970

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

408970

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

408970

shares

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

14.09

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

14.09

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

14.09

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

6715000

usd

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P2Y6M

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

P2Y6M

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

313000

usd

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

0

usd

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

0

usd

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

41858866

shares

CY2023Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

10000000

shares

CY2023

us-gaap

Treasury Stock Shares Acquired

TreasuryStockSharesAcquired

0

shares

CY2023

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-219000

usd

CY2021

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-171000

usd

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

-43001000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

6715000

usd

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P2Y6M

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

P2Y6M

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

313000

usd

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

0

usd

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

0

usd

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

10000000

shares

CY2023

us-gaap

Treasury Stock Shares Acquired

TreasuryStockSharesAcquired

0

shares

CY2023

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-219000

usd

CY2021

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-171000

usd

CY2023

us-gaap

Operating Income Loss

OperatingIncomeLoss

-40659000

usd

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

-43001000

usd

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

-35196000

usd

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

6715000

usd

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P2Y6M

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

P2Y6M

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

313000

usd

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

0

usd

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

0

usd

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2023Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

41858866

shares

CY2023Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

10000000

shares

CY2023

us-gaap

Treasury Stock Shares Acquired

TreasuryStockSharesAcquired

0

shares

CY2022

us-gaap

Treasury Stock Shares Acquired

TreasuryStockSharesAcquired

95021

shares

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

-35196000

usd

CY2023

us-gaap

Interest Expense

InterestExpense

12077000

usd

CY2022

us-gaap

Interest Expense

InterestExpense

4267000

usd

CY2022

us-gaap

Interest Expense

InterestExpense

4267000

usd

CY2021

us-gaap

Interest Expense

InterestExpense

10000

usd

CY2023

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

464000

usd

CY2022

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

814000

usd

CY2021

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

2066000

usd

CY2022

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

896000

usd

CY2023

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-219000

usd

CY2022

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-253000

usd

CY2021

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

-171000

usd

CY2023

us-gaap

Operating Income Loss

OperatingIncomeLoss

-40659000

usd

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

-43001000

usd

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

-35196000

usd

CY2023

us-gaap

Interest Expense

InterestExpense

12077000

usd

CY2022

us-gaap

Interest Expense

InterestExpense

4267000

usd

CY2021

us-gaap

Interest Expense

InterestExpense

10000

usd

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

7701000

usd

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3072000

usd

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-14000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-45035000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-44196000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-35220000

usd

CY2023

us-gaap

Revenues

1108605000

usd

CY2022

us-gaap

Revenues

905179000

usd

CY2021

us-gaap

Revenues

698991000

usd

CY2023Q4

us-gaap

Deposit Assets

DepositAssets

14600000

usd

CY2021

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

2066000

usd

CY2023

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

456000

usd

CY2022

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

896000

usd

CY2021

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

2124000

usd

CY2023

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

7000

usd

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

7701000

usd

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3072000

usd

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-14000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-45035000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-44196000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-35220000

usd

CY2023

us-gaap

Revenues

1108605000

usd

CY2022

us-gaap

Revenues

905179000

usd

CY2021

us-gaap

Revenues

698991000

usd

CY2023Q4

us-gaap

Deposit Assets

DepositAssets

14600000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

-41019000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

-43794000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-4016000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-402000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-45035000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-44196000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-35220000

usd

CY2023

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

-8000

usd

CY2022

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

82000

usd

CY2021

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

58000

usd

CY2023

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

464000

usd

CY2022

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

814000

usd

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

7701000

usd

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3072000

usd

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-14000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-45035000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-44196000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-35220000

usd

CY2023

us-gaap

Revenues

1108605000

usd

CY2022

us-gaap

Revenues

905179000

usd

CY2021

us-gaap

Revenues

698991000

usd

CY2023Q4

us-gaap

Deposit Assets

DepositAssets

14600000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

-41019000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

-43794000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

-34052000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-4016000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-402000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-1168000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-45035000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-44196000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-35220000

usd

CY2023

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

-8000

usd

CY2022

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

82000

usd

CY2021

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

58000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

-41019000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

-34052000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Foreign

IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

-402000

usd

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-45035000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-44196000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-35220000

usd

CY2023

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

-8000

usd

CY2022

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

82000

usd

CY2023

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

464000

usd

CY2022

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

814000

usd

CY2021

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

2066000

usd

CY2023

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

456000

usd

CY2022

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

896000

usd

CY2021

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

2124000

usd

CY2023

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

7000

usd

CY2022

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

11000

usd

CY2021

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

-15000

usd

CY2023

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-805000

usd

CY2022

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-431000

usd

CY2021

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-1799000

usd

CY2023

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-798000

usd

CY2022

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-420000

usd

CY2021

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-1814000

usd

CY2023

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

-342000

usd

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

476000

usd

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

310000

usd

CY2023

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2022

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2021

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2021

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

2124000

usd

CY2023

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

7000

usd

CY2022

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

11000

usd

CY2021

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

-15000

usd

CY2021

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

-15000

usd

CY2023

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-805000

usd

CY2023

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-805000

usd

CY2022

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

11000

usd

CY2022

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-431000

usd

CY2021

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-1799000

usd

CY2023

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-798000

usd

CY2022

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-420000

usd

CY2021

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-1814000

usd

CY2023

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

-342000

usd

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

310000

usd

CY2023

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2022

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2021

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2022

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.035

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

-0.092

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

0.025

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

0.304

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.191

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.267

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.584

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.001

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.017

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.017

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.003

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.003

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.003

CY2023

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.008

CY2022

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

-0.011

CY2021

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

-0.009

CY2023Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve

10017000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve

8610000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

2190000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

1860000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

71231000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

63772000

usd

CY2023Q4

trup

Deferredtaxassetnoncurrentdepreciationandamortization

2310000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

3179000

usd

CY2022

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-431000

usd

CY2021

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

-1799000

usd

CY2023

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-798000

usd

CY2022

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-420000

usd

CY2021

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-1814000

usd

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

476000

usd

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

310000

usd

CY2023

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2022

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2023

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.079

CY2022

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.035

CY2021

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.075

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

-0.092

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

0.025

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

0.304

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.267

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.584

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.001

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.017

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.017

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.003

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.003

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.003

CY2023

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.008

CY2022

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

-0.011

CY2021

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

-0.009

CY2023Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve

10017000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve

8610000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

2190000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

1860000

usd

CY2023Q4

trup

Deferredtaxassetnoncurrentdepreciationandamortization

2310000

usd

CY2022Q4

trup

Deferredtaxassetnoncurrentdepreciationandamortization

1421000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

1875000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

3179000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Tax Credit Carryforwards

DeferredTaxAssetsTaxCreditCarryforwards

1147000

usd

CY2023

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.079

CY2022

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.035

CY2021

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.075

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

-0.092

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

0.025

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

0.304

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.191

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.267

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.584

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.001

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.017

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.017

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.003

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.003

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

0.003

CY2023

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.008

CY2022

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

-0.011

CY2021

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

-0.009

CY2023Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve

10017000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve

8610000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

2190000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

1860000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

71231000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

63772000

usd

CY2022Q4

trup

Deferredtaxassetnoncurrentdepreciationandamortization

1421000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

1875000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Tax Credit Carryforwards

DeferredTaxAssetsTaxCreditCarryforwards

1147000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Credit Carryforwards

DeferredTaxAssetsTaxCreditCarryforwards

997000

usd

CY2023Q4

trup

Deferredtaxassetnoncurrentother

1995000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

90765000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

81500000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities Deferred Expense

DeferredTaxLiabilitiesDeferredExpense

1549000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

3603000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities Other

DeferredTaxLiabilitiesOther

3471000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Other

DeferredTaxLiabilitiesOther

2398000

usd

CY2023Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

8123000

usd

CY2022Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

7323000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

82642000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

85245000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

77507000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2603000

usd

CY2023Q4

us-gaap

Operating Loss Carryforwards

OperatingLossCarryforwards

71200000

usd

CY2023

us-gaap

Deferred Income Taxes And Tax Credits

DeferredIncomeTaxesAndTaxCredits

1100000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Tax Credit Carryforwards

DeferredTaxAssetsTaxCreditCarryforwards

1147000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Credit Carryforwards

DeferredTaxAssetsTaxCreditCarryforwards

997000

usd

CY2023Q4

trup

Deferredtaxassetnoncurrentother

1995000

usd

CY2022Q4

trup

Deferredtaxassetnoncurrentother

1661000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

90765000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

81500000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities Deferred Expense

DeferredTaxLiabilitiesDeferredExpense

1549000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

3103000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

3603000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities Other

DeferredTaxLiabilitiesOther

3471000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Other

DeferredTaxLiabilitiesOther

2398000

usd

CY2023Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

8123000

usd

CY2022Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

7323000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

82642000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

74177000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

85245000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

77507000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2603000

usd

CY2023Q4

us-gaap

Operating Loss Carryforwards

OperatingLossCarryforwards

71200000

usd

CY2023

us-gaap

Deferred Income Taxes And Tax Credits

DeferredIncomeTaxesAndTaxCredits

1100000

usd

CY2023

trup

Operating Loss Carryforward Expiration Date

OperatingLossCarryforwardExpirationDate

2026

CY2023

trup

Operating Loss Carryforwards Limitationson Use Value

OperatingLossCarryforwardsLimitationsonUseValue

500000

usd

CY2023

us-gaap

Valuation Allowance Deferred Tax Asset Change In Amount

ValuationAllowanceDeferredTaxAssetChangeInAmount

7700000

usd

CY2022Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

151000

usd

CY2021Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

138000

usd

CY2020Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

133000

usd

CY2023

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

72000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

8000

usd

CY2021

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

0

usd

CY2023

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

1000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

5000

usd

CY2021

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

5000

usd

CY2023Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

80000

usd

CY2022Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

151000

usd

CY2021Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

138000

usd

CY2022

us-gaap

Defined Contribution Plan Employer Discretionary Contribution Amount

DefinedContributionPlanEmployerDiscretionaryContributionAmount

0

usd

CY2023

us-gaap

Defined Contribution Plan Employer Discretionary Contribution Amount

DefinedContributionPlanEmployerDiscretionaryContributionAmount

0

usd

CY2021

us-gaap

Defined Contribution Plan Employer Discretionary Contribution Amount

DefinedContributionPlanEmployerDiscretionaryContributionAmount

0

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Credit Carryforwards

DeferredTaxAssetsTaxCreditCarryforwards

997000

usd

CY2023Q4

trup

Deferredtaxassetnoncurrentother

1995000

usd

CY2022Q4

trup

Deferredtaxassetnoncurrentother

1661000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

90765000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

81500000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities Deferred Expense

DeferredTaxLiabilitiesDeferredExpense

1549000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Deferred Expense

DeferredTaxLiabilitiesDeferredExpense

1322000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

3103000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

3603000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities Other

DeferredTaxLiabilitiesOther

3471000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Other

DeferredTaxLiabilitiesOther

2398000

usd

CY2023Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

8123000

usd

CY2022Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

7323000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

82642000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

74177000

usd

CY2023Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

85245000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

77507000

usd

CY2023Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2603000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

3330000

usd

CY2023Q4

us-gaap

Operating Loss Carryforwards

OperatingLossCarryforwards

71200000

usd

CY2023

us-gaap

Deferred Income Taxes And Tax Credits

DeferredIncomeTaxesAndTaxCredits

1100000

usd

CY2023

trup

Operating Loss Carryforward Expiration Date

OperatingLossCarryforwardExpirationDate

2026

CY2023

trup

Operating Loss Carryforwards Limitationson Use Value

OperatingLossCarryforwardsLimitationsonUseValue

500000

usd

CY2023

us-gaap

Valuation Allowance Deferred Tax Asset Change In Amount

ValuationAllowanceDeferredTaxAssetChangeInAmount

7700000

usd

CY2022Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

151000

usd

CY2021Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

138000

usd

CY2020Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

133000

usd

CY2023

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

72000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

8000

usd

CY2021

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

0

usd

CY2023

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

1000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

5000

usd

CY2023Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

80000

usd

CY2022Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

151000

usd

CY2021Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

138000

usd

CY2022

us-gaap

Defined Contribution Plan Employer Discretionary Contribution Amount

DefinedContributionPlanEmployerDiscretionaryContributionAmount

0

usd

CY2023

us-gaap

Defined Contribution Plan Employer Discretionary Contribution Amount

DefinedContributionPlanEmployerDiscretionaryContributionAmount

0

usd

CY2021

us-gaap

Defined Contribution Plan Employer Discretionary Contribution Amount

DefinedContributionPlanEmployerDiscretionaryContributionAmount

0

usd

CY2023

trup

Operating Loss Carryforward Expiration Date

OperatingLossCarryforwardExpirationDate

2026

CY2023

trup

Operating Loss Carryforwards Limitationson Use Value

OperatingLossCarryforwardsLimitationsonUseValue

500000

usd

CY2023

us-gaap

Valuation Allowance Deferred Tax Asset Change In Amount

ValuationAllowanceDeferredTaxAssetChangeInAmount

7700000

usd

CY2022Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

151000

usd

CY2021Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

138000

usd

CY2020Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

133000

usd

CY2023

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

72000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

8000

usd

CY2021

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

0

usd

CY2023

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

1000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

5000

usd

CY2021

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

5000

usd

CY2021Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

138000

usd

CY2022

us-gaap

Defined Contribution Plan Employer Discretionary Contribution Amount

DefinedContributionPlanEmployerDiscretionaryContributionAmount

0

usd

CY2023

us-gaap

Defined Contribution Plan Employer Discretionary Contribution Amount

DefinedContributionPlanEmployerDiscretionaryContributionAmount

0

usd

CY2021

us-gaap

Defined Contribution Plan Employer Discretionary Contribution Amount

DefinedContributionPlanEmployerDiscretionaryContributionAmount

0

usd

CY2023Q4

us-gaap

Equity Method Investments

EquityMethodInvestments

300000

usd

CY2023

us-gaap

Related Party Transaction Amounts Of Transaction

RelatedPartyTransactionAmountsOfTransaction

2200000

usd

CY2022

us-gaap

Related Party Transaction Amounts Of Transaction

RelatedPartyTransactionAmountsOfTransaction

3500000

usd

CY2023

us-gaap

Proceeds From Dividends Received

ProceedsFromDividendsReceived

14900000

usd

CY2023Q4

us-gaap

Equity Method Investments

EquityMethodInvestments

300000

usd

CY2023

us-gaap

Related Party Transaction Amounts Of Transaction

RelatedPartyTransactionAmountsOfTransaction

2200000

usd

CY2022

us-gaap

Related Party Transaction Amounts Of Transaction

RelatedPartyTransactionAmountsOfTransaction

3500000

usd

CY2023

us-gaap

Proceeds From Dividends Received

ProceedsFromDividendsReceived

14900000

usd

CY2023

us-gaap

Related Party Transaction Amounts Of Transaction

RelatedPartyTransactionAmountsOfTransaction

2200000

usd

CY2022

us-gaap

Related Party Transaction Amounts Of Transaction

RelatedPartyTransactionAmountsOfTransaction

3500000

usd

CY2023

us-gaap

Proceeds From Dividends Received

ProceedsFromDividendsReceived

14900000

usd

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001371285-24-000029-index-headers.html	Edgar Link	pending
0001371285-24-000029-index.html	Edgar Link	pending
0001371285-24-000029.txt	Edgar Link	pending
0001371285-24-000029-xbrl.zip	Edgar Link	pending
ex1010q42023.htm	Edgar Link	pending
ex109q42023.htm	Edgar Link	pending
ex211q42023.htm	Edgar Link	pending
ex231q42023.htm	Edgar Link	pending
ex311q42023.htm	Edgar Link	pending
ex312q42023.htm	Edgar Link	pending
ex321q42023.htm	Edgar Link	pending
ex322q42023.htm	Edgar Link	pending
ex41descriptionofcapitalst.htm	Edgar Link	pending
ex971clawbackpolicy.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trup-20231231.htm	Edgar Link	pending
trup-20231231.xsd	Edgar Link	pending
trup-20231231_g1.jpg	Edgar Link	pending
trup-20231231_g2.jpg	Edgar Link	pending
trup-20231231_cal.xml	Edgar Link	unprocessable
trup-20231231_def.xml	Edgar Link	unprocessable
trup-20231231_lab.xml	Edgar Link	unprocessable
trup-20231231_pre.xml	Edgar Link	unprocessable
trup-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRUP
TRUPANION, INC. Stock $trup

2024 Q1 Form 10-K Financial Statement

#000137128524000029 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRUP TRUPANION, INC. Stock $trup

2024 Q1 Form 10-K Financial Statement

#000137128524000029 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRUP
TRUPANION, INC. Stock $trup